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Chronic obstructive pulmonary disease (COPD) is the third leading cause of morbidity and 
mortality in the United States and an epidemic worldwide. COPD pathologically manifests as 
emphysema, which is characterized by the abnormal and permanent airspace enlargement. 
Current research strives to understand the exact sequence of events triggering and leading to the 
progression of this disease, with the continued hope of finding a cure. The overarching aim of the 
current study was to investigate the role for the receptor for advanced glycation end products 
(RAGE) and a distal bronchial progenitor cell population (DBPCs) in mediating alveolar damage 
and repair using murine models of emphysema. 
RAGE has gained importance in the context of COPD in the past decade. Highly expressed in 
normal adult lung tissue; its expression is altered in the context of lung injury. The present study 
tests the hypothesis that RAGE mediates cigarette smoke induced alveolar injury based on its 
previously described pro-inflammatory function. RAGE knockout mice (RAGE-/-) were used to 
investigate the contribution of this receptor towards the development of cigarette smoke induced 
emphysema. Our data indicates RAGE’s key contribution towards cigarette smoke induced 
emphysema, mediated through neutrophil recruitment and increased loss of tissue elastance. 
Emphysema is thought to result from the disruption of a delicate balance that exists 
within the alveolar compartment; accentuated by failure at endogenous attempts to repair in the 
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presence of extensive inflammation and loss of underlying basement membrane. Using a 
transgenic mouse line (CC10-Cre x Rosa26-LacZ) developed in our laboratory, we trace and 
confirm the migration of a distal bronchial progenitor cell population from the bronchoalveolar 
duct junction (BADJ)/ terminal bronchioles into the adjacent injured alveolar compartment. We 
further confirm our findings in a knock-in mouse line (CC10-iCre X Rosa26-LacZ) and thereby 
authenticate the contribution of these progenitor cells towards repopulating the injured alveolus.  
This study shows that RAGE mediates early neutrophil recruitment leading to the 
pathogenic progression of alveolar damage and elucidate the contribution of a CC10 expressing 
bronchial progenitor arising from the distal airways leading to alveolar repopulation in the 
context of emphysema. 
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1.0  CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
Chronic obstructive pulmonary disease (COPD) is estimated to effect greater than 24 million 
individuals across the United States of America [1]. It has been formally defined by the Global 
Initiative of Chronic Obstructive Lung Disease (GOLD) as “ a common preventable and 
treatable disease, characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the lung in 
response to noxious particles and gases” [2]. Irreversible airflow limitation is a common 
byproduct of this disease, which comes in varying degrees of contribution from small airways 
disease (obstructed bronchi) and extensive destruction of the alveolar parenchyma (emphysema). 
1.1 BURDEN OF COPD 
COPD is largely a preventable disease, however it still remains a major cause of morbidity and 
mortality throughout the world. The Global burden of disease predicts that COPD will become 
the third leading cause of death globally by 2020 and newer estimates predict that it will be the 
fourth leading cause by 2030 [3]. Other co-morbid chronic conditions such as musculoskeletal 
diseases, metabolic diseases, cardiovascular diseases, hematological diseases, gastro-intestinal 
diseases to name a few increase the morbidity observed in COPD patients and make treatment 
more difficult [4]. Being the third leading cause of death in the United States, COPD presents a 
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significant economic and social burden to the country at large. Although the estimates are far 
from being exact due to various limitations in data availability, population sizes etc. they do 
serve as an indicator of rising costs to the national healthcare sector. The major contributor to 
these costs comes from hospitalization and related outpatient services [5]. 
1.2 RISK FACTORS CONTRIBUTING TO COPD 
1.2.1 Cigarette smoking and genetic factors 
Perhaps the most predominant factor leading to the development of COPD comes in the form of 
cigarette smoke exposure [6]. However, ~10 % present with COPD in absence of cigarette 
smoke exposure. The interaction of cigarette smoke and other environmental exposures and the 
genetic make up of an individual largely determine their susceptibility to developing the disease. 
One of the best and well-characterized examples of this comes from COPD patients deficient for 
a serine protease inhibitor α1 anti-trypsin (A1AT), which is usually ~1 to 3 % of all cases. Low 
levels of A1AT in combination with exposure to cigarette smoke or toxic fumes can elevate the 
development of emphysema [7], although some A1AT patients can develop emphysema without 
smoking.  
Matrix metalloproteinase12 (MMP-12), also known as macrophage elastase produced by 
macrophages have been described to play a vital pro-inflammatory role in the distal lung in 
response to cigarette smoke induced emphysema [8, 9]. An investigation of single nucleotide 
polymorphisms (SNP) in this gene as a function of forced expiratory volume in 1 second (FEV1) 
in approximately 8300 subjects, led to the discovery of a significant association between the 
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minor allele of SNP rs2276109 in the MMP-12 gene and a decreased risk of smoke induced 
COPD [10].  
1.2.2 Age and gender 
Age has been attributed to be a factor to consider in the development of COPD [7]. However, it 
remains unclear if age by itself contributes to the development of this disease or if it is a 
manifestation of cumulative exposures through the course of one’s life that manifest as the 
disease in one’s later years in addition to diminished endogenous repair processes. Gender, is 
another factor that has been studied and its contribution as a factor debated. In the past, COPD 
had been associated to have a higher prevalence in men compared to women owing to greater 
exposure to cigarette smoke or occupational fumes [11, 12]. However, more recent studies 
indicate that women are more susceptible to the damaging effects of cigarette smoke in 
comparison to their male counterparts [13].  
1.2.3 Occupational exposure, outdoor and indoor air pollutants 
Occupational exposure to noxious dusts, fumes or vapors probably does not initiate but 
contributes to COPD. An analysis involving over 10,000 subjects showed almost 19.2% of the 
COPD cases were exposed to work-related exposures [14]. The occupations that were reported to 
have the highest odds includes freight, stock, material handlers, record processing and 
distribution clerks, vehicle mechanics and the armed forces [14]. The risks of occupational 
exposures leading to COPD in less regulated, lower income countries are greater than in better-
regulated, high-income countries. Further, indoors exposure to burning of biomass fuel (wood, 
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cow dung, coal, crop residues etc.) to cook and heat without sufficient ventilation pose a major 
risk of acquiring COPD especially in developing countries [15, 16]. Outdoor air pollutants 
mainly vehicular and industrial air pollution poses a lower risk to the development of COPD in 
comparison to indoor pollutants. About 2% of the COPD cases may arise from outdoor pollution 
in middle to lower income countries and less than 1% in developed countries [7]. Other risk 
factors include exposures and respiratory infections during early childhood and adolescence 
when the lungs are developing which can pre-dispose these individuals to developing COPD 
later in life due to limited functional reserve. Additionally, socio-economic status can influence 
exposures to cigarettes, indoor/outdoor pollutants, nutrition and incidence of infections. 
1.3 COPD- PATHOPHYSIOLOGY 
COPD manifests through a variety of abnormalities throughout the respiratory tract including 
chronic bronchitis in the upper airways, small airway obstruction and emphysema in the alveolar 
compartment of the lung. Small airway obstruction and emphysema are characterized by 
significant airflow limitation. In the airways there is narrowing of the airway lumen due to 
mucus hyper-secretion, abnormal inflammatory response and fibrosis. In the alveolar space 
breakdown of extracellular matrix particularly the elastic cable network by excessive proteolytic 
activity leads to reduced elastic recoil manifesting as reduced airflow. Airflow limitation is 
typically progressive and distinguished by an abnormal and chronic inflammatory response to 
inhaled noxious gases or particulate matter (including industrial and environmental pollutants), 
in the case of COPD it is mostly due to long-term exposure to cigarette smoke. The common 
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symptoms of this disease include shortness of breath (lack of sufficient gas exchange) and 
persistent cough with phlegm (increased mucus production).  
Bronchitis is the inflammation of the cells lining the upper airways and bronchi. Acute 
bronchitis characterized by coughing may accompany a cold and typically clears within a span of 
2 weeks. Chronic bronchitis, on the other hand is accompanied by prolonged coughing with 
sputum production for almost a month, 3 months of a year, over two consecutive years. Chronic 
bronchitis is commonly characterized by excessive mucus production leading to narrowing of 
airway lumen and inflammatory cell infiltration of the bronchial epithelium. Mucus producing 
goblet cells lining the airways proliferate (hyperplasia) and increase their production of mucus 
(hypertrophy) contributing to this phenotype. 
Emphysema is characterized by the permanent destruction and enlargement of alveoli. It 
may or may not manifest clinically in isolation of chronic bronchitis. This component of COPD 
is thought to manifest from noxious gas exposure inducing cellular oxidative stress, loss of 
alveolar epithelium (by apoptosis or necrosis) and proteolysis of the extracellular matrix (ECM) 
functioning as a scaffold for the alveolar epithelial cells to adhere. Airflow limitation that in 
emphysema may occur through loss of alveolar ECM leading to the collapse of the alveolar 
structure and subsequent to this loss of the alveolar unit leading to collapse of the distal bronchi 
further constricting their lumen contributing to insufficient airflow.   
 
1.3.1 Pathogenic mechanisms in Emphysema 
The pathologic enlargement and inflammation of the alveolar compartment of the lung 
characterize emphysema. Our understanding of mechanisms that serve as triggers instrumenting 
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such damage and destruction of the lung parenchyma is a work in progress. Exposure to cigarette 
smoke is critical. Other environmental factors may contribute as well including respiratory 
infections. Genetic factors are also important and several have been identified since the 
identification of alpha-1-antitrypsin over 50 years ago. Some genes that have been suggested to 
be associated with the disease from multiple genome wide associated studies, include 
interleukin-6 receptor (IL-6R), hedgehog interacting protein (HHIP), family with sequence 
similarity 13 member A1 (FAM13A), iron-responsive element binding protein (IREB2) and a-
nicotinic acetylcholine receptor (CHRNA 3/5) locus to name a few [17]. Currently, established 
mechanisms propose an imbalance of protease-anti-protease levels, oxidant induced injury, 
increased inflammation, inhibition of histone de-acetylases and alveolar wall cell apoptosis. 
Genetically mutated/targeted mice applied to cigarette smoke exposure have served and continue 
to serve as good models to study relative contributions of different genes and exogenous agents 
towards lung alveologenesis and emphysematous destruction of the alveolar compartment. 
1.3.1.1 Protease- anti-protease imbalance 
The protease-anti-protease hypothesis has been the main proposed mechanism of emphysema for 
over half a century now. A delicate balance between proteases that breakdown connective tissue 
and anti-proteases that protect from this destruction; closely dictate lung maintenance [18]. The 
first example of this came from work by Laurell and Eriksson who found that patients deficient 
for α1 anti-trypsin (A1AT) were at an increased risk of early development of emphysema [19]. 
A1AT, a protein made by the liver, inhibits neutrophil-derived neutrophil elastase in the lung, the 
absence of which allows for uncontrolled elastin degradation leading to emphysema. Gene 
mutations in A1AT can lead to the production of abnormal protein that is unable to leave the 
liver and enter circulation [20]. Further, clinical studies have shown an increased prevalence of 
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COPD in patients with chronic liver disease [21]. Several other proteases have later been 
implicated in connective tissue damage using animal models of emphysema (discussed later). 
Elastin seems to be the critical target of proteases, the loss of which can lead to loss of elastic 
recoil important to alveolar function. In addition to degrading elastin/connective tissue 
components, proteases produce elastin fragments that displayed chemotactic potential serving in 
a positive feedback loop to recruit more inflammatory cells (mainly macrophages and 
neutrophils) to propagate alveolar destruction [8, 22, 23]. 
1.3.1.2 Inflammation 
Study of bronchial biopsies from smokers with mild-moderate COPD indicated elevated 
inflammation in their lungs [24]. Both the innate and adaptive immune systems have been shown 
to be active in emphysema. The recruitment of inflammatory cells to the lung environment leads 
to release of proteases and cytokines that mediate alveolar destruction and aberrant lung 
remodeling. The most dramatic of which are the macrophages that comprise the vast majority of 
inflammatory cells in the lung parenchyma and show a 5-10 fold increase in recruitment to the 
lung on chronic cigarette smoke exposure [25]. Morphometric analysis of macrophages in the 
tissue and alveolar spaces of patients with emphysema indicated a 25-fold increase in 
macrophage numbers when compared to normal smokers [26]. Macrophages once activated by 
cigarette smoke can secrete elastolytic matrix metalloproteinases (MMPs) like MMP-9 and 
MMP-12 (macrophage elastase). Neutrophil elastase may also be found in macrophages once 
they are taken up from apoptotic neutrophils [27, 28]. Further activated macrophages secrete 
other nuclear factor κB (NF-κB) transcription regulated cytokines like tumor necrosis factor α 
(TNF-α), interleukin-8 (IL-8), monocyte chemotactic protein-1 (MCP-1), leukotriene B4 and 
various CXC chemokines that serve to attract neutrophils and lymphocytes into the lung [29, 30]. 
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 Cigarette smoke has been shown to increase the circulating levels of neutrophils and 
reduce the deforming capacity of these cells thereby sequestering them in the circulating 
capillaries [31]. Neutrophils have the potential to secrete neutrophil elastase, proteinase 3, 
cathepsin G and MMPs 8 as well as 9 capable of destroying connective tissue leading to 
emphysema [32, 33].  
 Several studies have observed an increase in T lymphocytes in the lung parenchyma and 
airways of smokers, with a higher increase in CD8+ T cells in comparison to CD4+ T cells [26, 
34-36]. This observation was mirrored in mice using cigarette smoke induced emphysema that 
showed a predominance of T cells which had a direct correlation with the extent of emphysema 
[37]. Specifically, CD8+ cells have been shown to be capable of mediating cytolysis and 
apoptosis of alveolar epithelial cells through the release of perforins, TNF-α and granzyme-B 
[38].   
 Imbalances in levels of histone acetylases and deacetylases (HDACs) have been ascribed 
to chromatin remodeling resulting in pro-inflammatory gene expression therefore enhancing 
inflammation in the lung. Macrophages isolated from the lungs of cigarette smokers as well as 
animals exposed to cigarette smoke express reduced levels of HDAC [39, 40]. Reduced levels of 
HDAC result in the unwinding of the chromatin, allowing access to transcription factors to 
transcribed inflammatory genes. Conclusive evidence is yet to be gathered to confirm this 
proposed mechanism. 
1.3.1.3 Oxidative stress 
Cigarette smoke comprises of a complex mix of chemicals, free radicals and reactive 
oxidants. The equilibrium between extracellular and intracellular anti-oxidants that fight the 
toxic insult from noxious gases or vapors is essential to normal lung function. It is when this 
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equilibrium is disturbed oxidative stress occurs. Human leukocytes isolated from smokers have 
been described to release increased numbers of oxidants as compared to non-smokers [41]. This 
finding showcased increased oxidative stress in the lungs of smokers caused by the progressive 
accumulation of macrophages and neutrophils in the alveolar space.  Free radicals generated by 
oxidative stress can attack polyunsaturated fatty acids on the cell membrane causing lipid 
peroxidation. This leads to the generation of hydrogen peroxides and long-lived aldehydes that 
perpetuate the damage. Further support for this finding comes from analysis of plasma and 
BALF from healthy smokers and COPD patients with acute exacerbations who had elevated 
levels of lipid peroxidation products and compared to healthy non-smokers [42-44].  
Cigarette smoke-induced oxidant damage has been shown to partially damage elastin and 
collagen promoting damage by elastases and collagenases respectively [45]. Further, cigarette 
smoke has been shown to interfere with elastin synthesis and repair of damaged elastin leading to 
emphysematous changes [46]. Oxidants (like reactive oxygen species) have been known to 
potentiate proteolytic activity in COPD by the activation of these protease precursors [47]. 
Further direct oxidation of methionine residues in the active site of A1AT have been shown to 
inhibit this enzyme’s activity and though to contribute to the imbalance [48, 49]. Anti-oxidant 
enzymes characterized in the lungs of normal healthy individuals include superoxide dismutase 
(SOD), catalases and glutathione system [50]. Although studies have shown elevated glutathione 
levels in the BALF of chronic smokers [51], subsequent investigations have indicated that 
cigarette smoke depleted gluthathione in a dose-dependent manner implying insufficient levels to 
counter-act oxidative damage under acute smoke exposures [42]. Thus, the abnormal alveolar 
enlargement may result from oxidative stress (constituting cigarette smoke) on epithelial cells, 
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resulting in perpetuation by inflammatory cells in the airspaces in parallel with impaired cellular 
repair (anti-oxidant enzymes).   
1.3.1.4 Loss of alveolar structure and apoptosis 
Surfactants are thought to contribute towards alveolar structure and integrity. Studies conducted 
blocking neutral lipid metabolism in lysosomal acid lipase knockout mice developed 
emphysema, had elevated levels of neutrophils and macrophages, increased expression of pro-
inflammatory cytokines and MMPs [52]. Further the mice lacking surfactant protein A, C and D 
showed emphysema and inflammation-related alterations in their lungs [53]. Additionally, 
clinical studies have indicated that elevated serum levels of SP-D may act as a biomarker for 
patients with stable COPD as compared to their healthy controls [54, 55]. The alveolar space and 
the cells lining it share a certain degree of plasticity allowing for them to adjust on a continuous 
basis, disruption of this balance can lead to emphysematous changes.  
Alveolar cell apoptosis and loss of alveolar structural equilibrium (matrix loss) had been 
thought to be instrumental to the development of emphysema [56]. Contrary to these findings, 
epithelial cell apoptosis induced by intra-tracheal microcystine (apoptosis inducer) in mice 
showed changes in lung morphology that were similar to mild acute lung injury camouflaged as 
emphysema; different from alveolar changes in mice that received porcine pancreatic elastase 
(PPE) [57]. Apoptosis of epithelial cells may not be the initiating event leading to emphysema, 
but rather a downstream event of other triggers that are yet to be uncovered. 
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1.4 COPD-ASTHMA OVERLAP 
COPD shares features that are common with asthma, namely both are inflammatory diseases that 
affect the small airways, characterized by bronchial hyper-responsiveness and broncho-
contriction due to increased mucus production leading to air-flow limitation. At the same time 
they also are distinctly different; in that COPD affects both the airways as well as the alveoli, 
while asthma exclusively affects the airways. Besides both being chronic inflammatory diseases, 
the nature of inflammation observed is quite different [58]. In COPD, the inflammatory response 
is mostly characterized by macrophages, neutrophils, and cytotoxic CD-8+ T-lymphocytes [35, 
59]. In contrast, the inflammatory response in asthma is mainly eosinophil and CD4 T-
lymphocyte driven. There is clinical data to indicate that the nature of inflammation dictates the 
response to treatment by pharmaceutical drugs. Corticosteroids have been shown to be more 
efficacious in treating eosinophillic asthma as compared to the more neutrophillic COPD [60, 
61]. Clinically asthma and COPD do co-exist in some cases, which make its diagnosis 
challenging especially in older patients and its treatment complicated [62]. 
 
1.5 COPD-DIAGNOSIS AND ASSESSMENT 
A patient who presents with symptoms that include shortness of breath and chronic cough with 
sputum and has prior exposure to any of the risk factors discussed in the earlier section is to be 
diagnosed for COPD [2]. In addition, the complete medical history of the patient needs to be 
assessed in conjunction with their diagnosis to tailor treatment to the patient’s needs.  
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Spirometry provides a reproducible and objective measure of airflow limitation. It is used 
to measure the maximum amount of air exhaled after a maximal inspiration (forced vital 
capacity, FVC) and the volume of air exhaled with the first second of this expiration (forced 
expiratory volume-1, FEV1). The ratio of these two parameters (FEV1/FVC) collected from the 
spirometric assessment is then calculated and evaluated in comparison to a reference table 
additionally accounting for age, gender, height, weight etc [63]. Further, a FEV1/FVC ratio < 0.7 
on bronchodialation is used to confirm airway constriction and make a definitive diagnosis of 
COPD [2]. 
Since COPD is often a progressive disease occurring over a prolonged span in time; it 
does have systemic effects such as weight loss, musculoskeletal dysfunction and nutritional 
abnormalities [64]. Several studies highlight an increased risk in patients with COPD of 
developing other chronic diseases; this is particularly striking in the case of COPD and lung 
cancer. The precise reason for this association is not completely understood, but may be related 
to the lack of effective clearance of carcinogens or presence of common susceptibility genes or 
similar sensitivity to environmental risk factors [65-68]. 
Additional analysis may involve imaging through X-Ray or a computed tomography 
(CT) scan of the chest. A1AT genetic screening may also be performed if the patient presents 
with emphysema in the lower lobes or has a familial history. Body plethysmography is used to 
measure lung volumes and the diffusing capacity (DLCO) to determine the functional capacity of 
the lungs as a result of emphysema. In determining the need for additional oxygenation, the 
patient’s oxygen saturation is tested by pulse oximetry. Assessing exercise capacity through a 
walk test may also indicate the level of physical disability or improvement in physiological 
function as an effect of clinical rehabilitation [2]. 
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1.6 COPD-TREATMENT 
Smoking cessation is clearly the best way to prevent COPD and blunt the natural progression of 
COPD. This may involve the adoption of nicotine replacement strategies such as nicotine 
patches, gum or spray, which have all shown to significantly aid in abstinence from smoking 
[69-71]. Recent myocardial infarction or stroke, unstable coronary artery disease or untreated 
peptic ulcer diseases may be reasons to withhold treatment by nicotine replacement [72]. Weight 
loss and nutritional deficiencies are common manifestations in patients with advanced COPD; 
hence their diet needs to be a balanced one with sufficient caloric intake accompanied by 
exercise to prevent muscle atrophy and insufficient nutrition [2]. 
 Pharmacologic treatment options for COPD used in isolation or combination include 
bronchodilators like Beta2 (β2) agonists, anti-cholinergics as well as inhaled corticosteroids and 
phosphodiesterase-4 (PDE-4) inhibitors. Bronchodilators enable the opening up of constricted 
airways by modulating airway smooth muscle tone, in doing so they help improve lung function 
(increase FEV1) and the emptying of the lungs. The most important of these are β2-agonists, 
which act on β2 adrenergic receptors present on airway smooth muscle cells causing the release 
of cyclic adenine mono-phosphate (c-AMP) which counter-acts broncho-constriction. 
Ipratropium, oxitropium and tiotropium bromide (long-acting) are commonly used anti-
cholinergics that aid in blocking the binding and further activation by acetocholine on muscarinic 
receptors, which impact the underlying airway tone. Inhaled short-acting anti-cholinergics 
provide longer bronchodialatory effect in comparison to short-acting β2-agonists, evident up to 8 
hours from the time of administration [73]. Anti-Cholinergics may act to reduce mucus 
hypersecretion, however β2-agonists and mucolytics may have no contribution [74]. Inhaled 
corticosteroids are used to treat inflammation, however their efficacy in COPD as opposed to 
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asthma in terms of countering pulmonary and systemic inflammation is debated. Further the 
long-term effects and safety of using inhaled corticosteroids is still to be determined. 
Roflumilast, a PDE-4 inhibitor (anti-inflammatory) recently approved for COPD; has been 
shown to reduce moderate to severe exacerbations in 15-20% of patients with severe to very 
severe COPD who received this in combination with an inhaled corticosteroid [75].  
Supplementary pharmacologic treatments may include A1AT augmentation therapy for 
patients deficient in A1AT (rare and expensive), antibiotic treatment[76], vasodialators [77], 
mucolytic agents [78], anti-oxidant agents, vaccines [79] and immunoregulators [80].  
COPD patients with chronic respiratory failure and low resting levels of oxygen 
(hypoxemia) showed significantly improved survival rates with long term oxygen therapy [81]. 
Non-invasive ventilation is increasingly used to treat stable very severe COPD. Long term 
oxygen therapy implemented in combination with external ventilation has been used in patients 
who present with daytime hypercarbia (increased levels of circulating carbon-dioxide) leading to 
better survival with no improvement to quality of life [82].  
Severe COPD patients with upper lobe emphysema and low exercise capacity make 
suitable candidates for lung volume resection surgery (LVRS); which involves removal of 
portions of the lung (pneumectomy) to reduce increased inflation from loss of alveolar units of 
the lung [83]. The procedure is thought to improve the mechanical efficiency of respiratory 
muscles by enabling them to better generate pressure. Further exacerbations are reduced through 
improved elastic recoil following surgery that in turn improves the expiratory flow of air [84]. A 
major limitation of LVRS remains that it has high mortality than medical management of severe 
COPD [85]. Lung transplantation on the other hand has led to regaining better functional 
capacity and quality of life. One of the major challenges has been availability of matched donor 
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organs and associated costs. COPD patients who undergo lung transplants are often faced with 
issues such as immune rejection, infections (fugal, viral or bacterial) and lymphoproliferative 
diseases [86]. 
Most treatment strategies currently used in the clinical realm cater to treating the 
symptoms associated with COPD; these provide temporary relief and delay mortality at best. 
While attempts continue to be made to understand the underlying cause of this complex disease, 
we are still far from finding a cure for it.   
1.7 ANIMAL MODELS OF EMPHYSEMA 
A number of different animals have been used to study emphysema over the years including 
monkeys, sheep, dogs, guinea pigs and rodents. However, in more recent times mice have proven 
to be the best model to study this disease given our elaborate understanding of their genome, 
relative ease of genetic manipulation, short breeding times with large litters and availability of 
probes/antibodies allowing for greater investigation [87]. The extent to which mice or other 
animal models do and do not replicate human physiological and pathologic processes must be 
kept in mind while trying to extrapolate findings in animal models to corresponding processes in 
humans. The use of exogenous agents such as proteases, oxidants, particulates, inhibitors and 
cigarette smoke have been used to model characteristic features of human emphysema. In 
addition, naturally occurring and genetically engineered mutants that result in airspace 
enlargement enable for better understanding of the roles of genes especially during lung 
development and even later in life. 
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1.7.1 Protease and chemical injury models 
Protease injury models date back to the studies performed by Gross, who instilled papain in rats 
and described emphysematous alterations in their lungs 50 years ago [88]. Intra-tracheal 
instillation of porcine pancreatic elastase (PPE) led to an initial loss in elastin and collagen in the 
lung. PPE exposure resulted in permanent loss of the alveolar extracellular matrix (ECM) 
thereby distorting the lung architecture. Although elastin and glucosaminoglycan (GAG) levels 
were restored later in the model; collagen levels remained enhanced. On close investigation of 
the elastin fiber assembly it was noted to have an abnormal morphology, similar to that seen in 
patients with emphysema [89]. Intra-tracheal PPE lead to an initial breakdown of elastin, which 
was followed by an endogenous inflammatory response leading to progressive damage observed. 
Studies performed using lathyrogen β-aminopropionile (BAPN), which inhibited cross-linking of 
elastin and collagen fibers resulted in worse emphysema implying the presence of attempts at 
endogenous repair [90]. Proteases such as PPE, neutrophil elastase, papain, proteinase-3 has been 
shown to contribute to panlobular emphysema and are useful to study the downstream effects of 
protease injury [91]. Human emphysema on the other hand develops as a result of prolonged 
exposures to cigarette smoke and hence the short-term protease-model may not mirror a 
homologous progression of the disease. The PPE model initially was thought to be limited to the 
study of mediators working downstream of protease injury in the lung, however given that most 
of the emphysema at 3-4 weeks is due to endogenous inflammation and destruction, it might 
replicate human disease better than previously thought. It also provides a simple model to 
perform preliminary analysis of downstream events particularly in the context of alveolar repair 
[92].  
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Repeated endotoxin (lipopolysaccaride, LPS) administration was shown to result in 
airspace enlargement [93]. Nitrogen dioxide and ozone, common oxidants in air predominantly 
caused lung injury [87]. Cadmium chloride (major constituent of cigarette smoke), coal dust and 
silica caused varying degrees of alveolar injury or fibrosis. Vascular endothelial cell growth 
factor recepter – 2 (VEGFR-2) inhibitor, used to model non-inflammatory emphysema; was 
characterized by airspace enlargement, alveolar epithelial cell apoptosis and loss of pulmonary 
arterial branching [94, 95]. Several other chemical agents have been utilized in the study of 
emphysema yet none have been able to reflect the damage induced by chronic cigarette smoke 
exposure in its entirety. 
1.7.2 Cigarette smoke model 
The cigarette smoke model involves the delivery of smoke from burning cigarettes into a 
chamber with controlled airflow dynamics. The first successful description of this model was in 
1990; guinea pigs were exposed to 10 cigarettes a day, 5 days a week, over 1,3,6 and 12 months 
and shown to develop emphysematous changes in their lungs and displayed similar lung 
dynamics on pulmonary function testing as found in humans [96]. Prolonged exposure to 
cigarette smoke led to neutrophilia, progressive accumulation of macrophages and CD4+ T-
lymphocytes. Halting cigarette smoke exposure failed to reverse the airspace enlargement 
observed [97]. 
Murine models of cigarette smoke exposure involved the use of previously described 
smoking chambers [98]. Mice can breathe only through their noses, their tracheas are mildly 
populated by ciliated epithelial cells thereby not enabling for much filtering of air inhaled. 
However, mice are able to tolerate 2 cigarettes at a time at least twice a day without their 
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carboxyhaemoglobin levels reaching toxic levels for over several months and develop a 
phenotype with similarities to that seen in human COPD. The airways in mice are sparsely 
populated by mucus producing cells, which are mostly if not always found in the trachea. Their 
airways are composed of ciliated epithelial cells and Clara cells, nevertheless they lack goblet 
cells. Mouse airways display much less branching than human airways and they further lack 
respiratory bronchioles. C57BL/6 and A/J strains of mice have extensive ciliated cells lining 
their airways with an increased density in the proximal regions. Long-term (~2 months) cigarette 
smoke exposure does not affect the numbers of clara cells, on the contrary it causes a loss in 
ciliated epithelial cells lining the airways and accumulation of inflammatory cells [92]. 
Neutrophils are the first to arrive in the lung from the very first cigarette followed subsequently 
by macrophages and T-lymphocytes. The early neutrophil recruitment is accompanied by 
significant breakdown of lung elastin and collagen. Antibodies against polymorphonuclear 
leukocytes and intraperitoneal administration exogenous A1AT have been shown to block this 
early neutrophil recruitment and elastin breakdown [99]. Mouse alveoli show increased 
inflammatory cell recruitment and alveolar enlargement in response to chronic cigarette smoke 
exposure similar to the response seen in humans. The enlargement in alveolar spaces was 
accompanied by an increase in alveolar duct size by 3-6 months and injury was mainly 
macrophage-mediated [100]. The extent of alveolar space enlargement seems to be mouse strain-
dependent, which in turn allows for future investigation of genes linked to COPD susceptibility. 
1.7.3 Naturally occurring airspace enlargement in genetic mutant mice  
Several inbred strains of mice have been known to spontaneous develop mutations leading to 
certain identifiable phenotypes. The airspace enlargement observed in these mice arises from 
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developmental abnormalities rather than targeted lung destruction. A classic example of this was 
observed in the case of tight skin (Tsk+/-) mice. The Tsk+/- mice have abnormal alveolar 
development and progressive airspace enlargement; resulting from a mutation in fibrillin-1 
involved in elastin assembly [101]. Other mutant strains previously described to develop 
enlarged alveoli include pallid mice [102], blotchy mice [103, 104] and beige mice [105]. 
1.7.4 Gene targeted mice and transgenic mice with airspace enlargement 
Advances in mouse genetic engineering have enabled gene-targeted approaches that 
allow the over-expression a specific gene or deletion of a gene of interest either under an 
endogenous cell-specific promotor (knock-in or knock-out) or by random insertion in the mouse 
genome (transgenic). This has facilitated the study of effects of loss or gain of a single gene 
under regulated experimental conditions thereby elucidating mechanistic aspects of the disease. 
Mouse embryonic lung development begins at around embryonic day 9.5, however 
alveologenesis involving the septation of the alveoli in the distal lung occurs between post-natal 
days 4 to 14 [106]. Loss of genes involved in laying down elastin fibers or it’s cross-linking can 
contribute significantly to the loss of structural integrity of the lung and impaired alveolar 
development. Platelet derived growth factor–A (PDGF-A), fibrulin-5, elastin and retinoic acid 
receptor-γ (RARγ) knockout mice deficient in elastin production or assembly had impaired 
alveolar septation [107-110]. A functional deletion of fibroblast growth factor receptor-3 and 4 
(FGFR-3 and FGFR-4) important for lung development shows increased collagen deposition 
with no change in structural elastin and abnormal alveologenesis [111]. 
Some gene-targeted mice develop spontaneous airspace enlargement with age. Mice 
carrying a targeted deletion of surfactant protein-D (SP-D) and tissue inhibitor of matrix 
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metalloproteinase-3 (TIMP-3) start of with normal lungs but develop progressive airspace 
enlargement as they age. This effect has been linked to matrix metaloproteinases (MMP) and 
inflammatory responses mediated by loss of these genes [112, 113]. 
Phenotypes observed in transgenic mouse models of emphysema may not completely reflect the 
exact features of disease due to the random integration of the transgene into the mouse genome, 
which could result in certain off-target effects [87]. The over-expression of platelet derived 
growth factor-B (PDGF-B), Interleukin-11 (IL-11), IL-6 and transforming growth factor-α in the 
lung were linked with developmental abnormalities [114-116]. Inducible over-expression of IL-
13, interferon-γ (IFN-γ) and mice over-expressing human MMP-1 has been observed to develop 
abnormally enlarged airspaces similar to human disease [117-119]. 
1.7.5 Cigarette smoke mediated Emphysema in gene-targeted mice 
Mouse strains deficient for specific proteases were exposed to long-term cigarette smoke to 
study the effect of loss of the specific gene towards alveolar maintenance or destruction. 
Elevated levels of expression of MMP-12 (or macrophage elastase) had been reported on human 
macrophages isolated from smokers in addition to immunohistochemistry staining on lung tissue 
from patients with emphysema. MMP-12 deficient mice (MMP-12-/-) were exposed to chronic 
cigarette smoke over 6 months and found to lack emphysema when compared to their wild-type 
counterparts [8]. This study inferred that MMP-12 was not only required for alveolar 
macrophage recruitment but also for alveolar destruction [120].  Neutrophil elastase inhibited by 
A1AT, when genetically deleted in mice rendered partial protection from long-term cigarette 
smoke induced emphysema [121]. These studies indicate the importance of elastases and 
inflammatory cell involved in the lung microenvironment leading to the development and 
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progression of the disease. Further, mice that were deficient for both tumor necrosis factor-α 
receptor type-I and II and IL-1β type-I receptor were protected from intratracheal porcine 
pancreatic elastase (PPE) exposure [122]. While MMP-9 is augmented in human subjects with 
emphysema, MMP-9 deficient mice were shown to develop similar inflammation and airspace 
enlargement on smoke exposure as their wild-type counterparts indicating the action of other 
compensatory mechanisms [123]. 
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2.0  THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) 
MEDIATED NEUTROPHIL RECRUITMENT DRIVES THE PATHOGENIC 
PROGRESSION OF EMPHYSEMA  
The Receptor for advanced glycation end products (RAGE) acts as a pattern recognition receptor 
and is highly expressed in the adult lung under normal conditions. Several studies in the recent 
years have pointed towards its involvement in chronic lung disease. In the current investigation, 
we aim to define the contribution of RAGE in the pathogenesis of emphysema using a RAGE 
global knockout (RAGE-/-) strain of mouse. RAGE-/- mice exposed to chronic cigarette smoke 
demonstrated partial protection from cigarette smoke induced alveolar enlargement when 
compared to their wild-type (RAGE+/+) counterparts. The RAGE-/- mice exposed to room air 
showed airspace enlargement at baseline when compared to their room-air exposed wild-type 
controls, indicating a role for RAGE in alveolar development. Lung physiology measurements 
displayed a significant decrease in tissue elastance of wild type mice that were exposed to 
cigarette smoke compared to their room-air exposed controls on bronchocontriction. Such a 
change in tissue elastance was not observed in the RAGE-/- smokers when compared to their air-
exposed controls.  Macrophages and neutrophils have been attributed as the main inflammatory 
cell types that are recruited to the inflamed lung where they release proteases leading to 
progressive damage. A significant impairment in recruitment of neutrophils was observed on 
acute cigarette smoke exposure in RAGE-/- mice as compared to their wild type counterparts. 
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The results from our study define a role for RAGE in promoting alveolar enlargement on 
cigarette smoke exposure, through neutrophil recruitment and perhaps increased loss of 
elastance. 
2.1 RAGE- BACKGROUND 
2.1.1 RAGE – structure, isoforms, ligands and signaling 
The receptor for advanced glycation end products (RAGE) was initially isolated and 
characterized from bovine endothelium [124]. RAGE, based on computation analysis of its 
amino-acid structure was found to share homology with the immunoglobulin superfamily [125]. 
The extracellular domain of RAGE contains one “V” type domain involved in ligand binding and 
two “C” type domains. Full-length RAGE in addition to the extracellular domain has a 
transmembrane domain and a cytosolic tail (43 amino acid) involved in intracellular signaling 
[125]. 
The other isoform of RAGE, soluble RAGE (sRAGE); lacks the transmembrane and 
intracellular domains found in full-length RAGE. sRAGE acts as a decoy receptor and binds to 
ligands that would normally bind full-length membrane bound RAGE, thereby blunting RAGE-
ligand mediated downstream signaling. Hence sRAGE has been thought to play a protective role 
by binding RAGE ligands and preventing their negative interaction with membrane bound 
RAGE. RAGE binding ligands like HMGB1 and S100A8/A9 complex also bind and signal 
through the toll-like receptor 4 (TLR4) [126-128]. The soluble form of the receptor (s-RAGE) 
exerts antagonistic effects by binding these ligands and preventing their signaling through 
 24 
membrane bound RAGE (m-RAGE) or other receptors like TLR4. Although the mechanisms by 
which it is produced are not clear, some studies suggest that is produced by proteolytic cleavage 
of membrane RAGE and some others suggest its directly produced by alternative splicing of 
RAGE mRNA [129-132]. 
Several ligands are known to interact with RAGE, such as DNA binding high mobility 
group box 1 (HMGB1) [133], S100 protein family members [134], advanced glycation end 
products (AGEs) [135], glycosaminoglycans [136], beta amyloid proteins [137] and extracellular 
matrix components like collagen I, collagen IV and laminin [138, 139]. Additionally, RAGE has 
been shown to heterodimerize with β2 integrin Mac-1 on leukocytes [140]. Ligands that bind 
RAGE may not specifically bind to and signal only through RAGE, an example being HMGB1 
that can also bind to toll-like receptor-2 and 4 (TLR2 and TLR4) [141, 142]. 
Binding of ligands to extracellular domain of RAGE triggers an intracellular signaling 
cascade mediated by the cytoplasmic domain. Diaphanous-related formin 1 (mDia1) belonging 
to the actin and microtubule polymerization family of proteins was shown to bind to the 
intracellular domain of RAGE and signal through Rac1 and Cdc42 mediating cellular migration 
pathways [143]. Activation of RAGE by binding of AGE-albumin demonstrated the activation of 
p21- Ras driven mitogen activated protein kinase (MAPK) signaling cascade, which in turn 
activates nuclear factor κB (NF-κB) that translocates to the nucleus and begins transcription 
[144]. NF- κB acts as a master transcriptional regulator and is capable of initiating the 
transcription of pro-inflammatory factors such as interleukin-6 (IL-6), tumor necrosis factor-α 
(TNF-α) and interferon-β (IFN-β) [145-148]. NF- κB has additionally been shown to function in 
a positive feedback loop and leads to an upregulation in RAGE expression in the presence of 
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elevated levels of RAGE ligands. While there is overall consensus that RAGE signaling leads to 
NF κB nuclear translocation, the sequence of intra-cellular signaling events is poorly understood. 
2.1.2 RAGE in the lung 
The membrane bound form of RAGE (m-RAGE) is highly expressed in normal adult lung tissue 
and has been shown to localize to the basolateral membrane of differentiated alveolar type-I 
epithelial cells [149]. RAGE is also expressed on bronchial smooth muscle cells, vascular 
endothelial cells, alveolar macrophages & transitioning alveolar type-II epithelial cells in the 
alveolar parenchyma (F. Katsuoka, 1997; J Bret et al, 1993). 
In vitro studies performed utilizing a human embryonic kidney cell line (HEK293) 
transfected with full length RAGE illustrated the role of RAGE in cell adhesion and spreading on 
collagen IV matrix [139]. These findings highlighted the contribution of RAGE to epithelial, and 
perhaps alveolar type-I cell (AT-I) cell adhesion, spreading and facilitating gaseous exchange in 
the lung. Further, expression of RAGE predominantly on AT-I epithelial cells (M. Shirasawa, 
2004) indicates its potential contribution to alveologenesis and the maintenance of normal lung 
homeostasis. 
2.1.3 RAGE and COPD 
Deregulated expression of RAGE in lung tissue has been observed in various animal injury 
models and clinical studies of pulmonary disorders such as fibrosis (L.E. Hanford, 2003; J.M. 
Englert, 2008; L. Ramsgaard, 2008), non-small cell lung adenocarcinoma [150-155] and acute 
lung injury [131, 156, 157]. Black and coworkers, showed elevated intensity of staining for 
 26 
RAGE in the alveolar walls of lung tissue from smokers with COPD [158]. Decreased levels of 
soluble RAGE, which acts in an antagonistic fashion to RAGE, were detected in the 
bronchoalveolar lavage fluid (BALF) from the lungs of chronic smokers with COPD [159, 160]. 
RAGE expression was increased following in vitro exposure to cigarette smoke extract in rat 
(R3/1) cells and human (A549) cells [161]. Further investigation by the same group 
demonstrated that RAGE expressed by alveolar macrophages stimulated by intra-tracheal 
delivery of cigarette smoke extract elicited an inflammatory response [162]. Together these 
studies indicate a potential role for RAGE in the pathogenesis of COPD. However, the direct 
involvement and contribution of RAGE to the development of emphysema has not been explored 
thus far. 
2.2 RAGE-MATERIALS AND METHODS 
2.2.1 RAGE knockout mice 
RAGE-/- mice were originally generated from a founder RAGE knockout colony provided by 
Dr. A. Bierhaus (University of Hiedelberg, Germany) [163]. RAGE-/- mice were backcrossed 
until 10 generations into the C57BL/6J background. Eight to twelve week old female mice were 
used in all the experiments designed. Age, sex and background matched wild type (C57BL/6J) 
mice were obtained from Jackson Laboratories. The animals underwent strict quarantine when 
transferred between animal facilities within the university. All animal experiments were 
reviewed and approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee 
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2.2.2 Cigarette smoke models 
2.2.2.1 Chronic cigarette smoke model 
RAGE-/- and wild type mice were exposed to 2 unfiltered cigarettes, 2 times a day, 5 days a 
week over 6 months using a smoking chamber [96] that had been adapted for use with mice [8]. 
The controls in each group were exposed to room-air and housed along with their smoke exposed 
counterparts. This model was characterized by acute neutrophilic inflammation followed by 
accumulation of macrophages and lymphocytes within days. 
2.2.2.2 Acute cigarette smoke model 
RAGE-/- and wild type mice were exposed to 2 unfiltered cigarettes. The controls in each group 
did not receive any cigarette smoke, instead were exposed to room air. This model was used to 
study neutrophil recruitment, which peaks generally around 4 hours post-exposure.  
2.2.3 Respiratory mechanics measurements 
We measured airway resistance (Rn), tissue damping (G), tissue elastance (H), dynamic 
resistance (R), dynamic elastance (E) and dynamic compliance (C) in response to methacholine 
challenge (Sigma, St. Louis, MO) using a computer-operated ventilator (Flexivent, Scireq, 
Montreal, QC). The mice were anesthetized intraperitonial with pentobarbital sodium (60mg/kg), 
a tracheotomy was performed and the animal attached to a mechanical ventilator. Each animal 
was given deep lung inflation to open out the airways and baseline pressure-volume-flow 
measurements were captured. The animal was further exposed to phosphate buffered saline (1x 
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PBS) followed by increasing concentrations of methacholine (1, 3, 10 & 30mg/ml) through a 
nebulizer for 10 seconds and their responses were recorded. 
The responses recorded using a forced oscillation technique were then fitted to a constant 
phase model to compute the various parameters. We then plotted these parameters as a function 
of the log transformed concentrations of methacholine to analyze the dose-response. The slopes 
of the curves generated indicate differences in overall responses between strains and their 
treatments. 
2.2.4 Tissue processing for histology and morphometry 
The mice were sacrificed by carbon dioxide inhalation, their chest wall exposed and their trachea 
was cannulated. The lungs were inflated with 10% normal buffered formalin (NBF) under 25cm 
water pressure for ten to fifteen minutes and processed as previously described [164]. The 
inflated lungs were further fixed in 10% NBF before being processed for paraffin embedding. 
Serial mid-sagittal sections were obtained and the desired staining performed. 
2.2.5 Gills staining for morphometric assessment 
The paraffin embedded parasagittal lung sections were de-paraffinized at 60°C for 30 minutes, 
followed by rehydration in xylenes and a gradient of ethanols. The rehydrated sections were then 
rinsed in distilled water for 5 minutes and stained in modified Gills stain (1:1 Harris 
hematoxylin: Harris Gills no.3 stain) overnight at room temperature. The sections were then 
washed in distilled water, fixed in dilute ammonium hydroxide for 5 minutes and dehydrated 
through ethanols and xylene. Cover slips were added to the slides and let to air-dry. 
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2.2.6 Morphometry 
Ten random fields of gills stained sections per animal were captured under 200X magnification 
using NIS-elements program as described earlier (5,6) (Nikon, Tokyo, Japan). The sections were 
analyzed using Scion Image (Scion Corp., Fredrick, MD) avoiding all ambiguous areas, airways, 
smooth muscle and vasculature. The computed average chord length (CL) served as a measure of 
the average alveolar diameter from each experimental subject and enabled quantification of 
alveolar enlargement (a measure of emphysema). 
2.2.7 Lung tissue homogenate preparation and immunoblotting 
Whole lung tissue isolated from the mice were first homogenized in isotonic buffer with CHAPS 
detergent (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM CHAPS) with protease inhibitors 
(100 µM 3,4-dichloroisocoumarin (DCI), 10 µM trans-epoxysuccinyl-L-leucylamido- (4-
guanidino) butane (E-64), 2 mM o-phenanthroline monohydrate- all from Sigma) and then 
sonicated briefly. The protein concentration of the total lung homogenates was quantitated using 
the BCA standard protein assay kit  (Thermo Fisher). 50µgs of protein per sample was separated 
by SDS-PAGE and transferred to PVDF membranes as described previously [165]. The 
membranes were blocked overnight in 5% nonfat dry milk/PBST for an hour at room 
temperature. The membranes were then incubated with 1:1000 Rabbit anti-mouse caspase-3 
(Cell Signaling) primary overnight at 4°C and 1:2,000 anti-rabbit HRP secondary antibodies for 
1 hr at room temperature. The membranes were washed with PBST (3x for 10 min) between 
primary and secondary antibody incubation. The reactive bands were visualized using the 
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chemiluminescence method (SuperSignal West Pico, Pierce). The same membranes were probed 
with GAPDH (1:500; Cell Signaling) as loading controls. 
2.2.8 Bronchoalveolar lavage fluid collection and processing 
At the various points of time post- acute cigarette smoke exposure; batches of mice were 
sacrificed by carbon dioxide narcosis. The chest cavity was exposed and the trachea of the mice 
was cannulated using a 22-guage intravenous catheter. The lungs of the animal were lavaged 
with 0.75 ml of 1x PBS three times. The volume returned from each lavage was collected and 
recorded. The lavage fluid was centrifuged at 300 G for 5 minutes at 4°C and the supernatent 
separated for supplementary analysis. The cell pellet was then re-suspended in hypotonic 
solution to lyse red blood cells (RBC) and then centrifuged at 300 G for 5 minutes at 4°C. The 
supernatent containing lysed RBCs was discarded and the pellet resuspended in 1x PBS. A small 
fraction of this cell supension was used to determine total cell counts using a hemacytometer and 
the remainder (approximately 200μl) was used to prepare cytospins. 
2.2.9 Cytospin preparation and analysis 
The cytospins were prepared at 500rpm for 5 mins and let to air dry. The cytospins were then 
stained using a modified romanowsky stain, for 30 seconds in each of the 3 solutions and then 
rinsed in running distilled water. The slides were let to air-dry before being imaged using a 
bright field microscope. Five to ten random fields were counted per animal (approximately 300 
cells) depending on the total number of cells recovered. The different cell populations were 
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recorded and their calculated percentages were used to extrapolate their individual counts in 1 ml 
of lavage fluid, using the total cell counts estimated earlier. 
2.2.10 Serum collection  
After sacrificing the mice, the fur and body wall was severed to expose their abdomen. The 
diaphragm was punctured to enable collapse of the lungs and a small incision was made to access 
the chest cavity. The inferior vena cava was severed, leading to the collection of blood in the 
chest cavity. The blood was drawn using a one ml syringe and collected in a serum separator 
tube (BD biosciences). These tubes were then centrifuged at 10,000 RPM for 10 minutes at 4 
degrees centigrade. The serum thus obtained was separated into a fresh tube and stored at -80°C 
for later analysis. 
2.2.11 Statistical analysis 
The quantitative data collected was analyzed using the Graphpad Prism 5 (Graphpad Prism Inc., 
La Jolla, CA). The values were represented as means ± standard error mean. An unpaired 2-tail 
student T-test was performed to determine statistical significance between strains and treatments. 
A p-value < 0.05 was considered statistically significant. 
 32 
2.3 RAGE-RESULTS 
2.3.1 Absence of RAGE affects the alveolar dimensions at baseline and protects from 
alveolar enlargement on chronic cigarette smoke exposure. 
The contribution of RAGE to cigarette smoke induced emphysema was investigated by exposing 
RAGE-/- mice to either chronic cigarette smoke or room-air for 6 months. Age and sex matched 
wild-type (C57BL/6J background) control mice were similarly exposed to cigarette smoke and 
room-air. Gills stained lung sections were examined for histologic and morphometric changes in 
the alveolar compartment as detailed in the Materials and Methods section. Wild-type 
(C57BL/6J) mice exposed to cigarette smoke (Figure1, Panel B) displayed enlarged alveoli when 
compared to their room air exposed controls (Figure1, Panel A). This histological observation 
was supported by morphometric analysis of chord lengths (CL), a measure of the alveolar 
diameter, as described in the materials and methods. As visualized in Figure 1E and Table 1, the 
wild-type mice exposed to cigarette smoke showed a 13.5% increase (p-value < 0.005) in chord 
length (29.7±11.3μm) when compared to their air-exposed controls (26.2±4.2μm). These results 
were replicated in a second study group with n=5-6 mice per strain per treatment group. A 14% 
increase in CL was observed in the second batch of chronic smoke exposed wild-type mice 
(Table 1). The alveolar enlargement observed in the wild type mice on cigarette smoke exposure 
was in corroboration with the expected phenotype. 
RAGE-/- mice demonstrated enlarged airspaces in the absence of smoke exposure 
(Figure 1, panel C) compared to wild type (Figure 1, panel A). The mean chord length of RAGE-
/- mice exposed to room air (30.1 ±3.6 μm) was significantly higher (p-value=0.00002) than 
room air exposed wild-type mice (26.2±4.2 μm) (Table 1). This trend was preserved in the 
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second batch of mice that were lavaged once before their lungs were inflated with 10%NBF for 
morphometric analysis. The enlarged airspaces observed in mice lacking RAGE expression 
likely represents altered alveolar development. 
 Cigarette-smoke exposure in the RAGE-/- mice did not lead to a significant increase in 
chord length as compared to their air-exposed controls (31.2±18.6μm vs. 30.1±3.6μm, p-
value=0.45) (Figure 1 and Table 1). Together these results imply that the absence of RAGE 
contributes to the development of emphysema. RAGE-/- mice were significantly protected from 
cigarette smoke induced airspace enlargement. Hence, airspaces in RAGE-/- mice are enlarged at 
baseline but protected from progressive enlargement in response to cigarette smoke.   
 
Table 1: Quantification of airspace enlargement using lung morphometry 
 
Mean chord length (CL) data from 2 independent experiments of chronic cigarette smoke exposures. Wild-
type (WT) mice were C57BL/6J background, congenic with the RAGE-/- mouse strain. The CL, the standard 
error of the mean (within the parentheses) as well as the percentage increase in CL with smoke exposure is 
displayed. The p-value indicated was derived from a 2-tailed student t-test. 
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Figure 1: Lack of RAGE leads to enlarged airspaces at baseline and protects from progressive airspace 
enlargement on chronic cigarette smoke exposure 
Panels A-D show representative images of gills stained sections of the lungs from the different treatment groups. 
Wild-type mice exposed to smoke (B) showed enlarged airspaces compared to their air-exposed controls (A). 
RAGE-/- mice showed no visually detectable difference in alveolar size on smoke exposure (D) when compared to 
their air-exposed controls (C). Panel E shows a graphical representation of Batch # 1- the mean chord length (μm), a 
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measure of alveolar diameter, calculated in each strain and treatment group. The * indicates a p-value < 0.05 on an 
unpaired 2-tailed student t-test, specifying statistical significance. The error bars indicate the standard error mean 
(SEM) for each group. 
2.3.2 Effect of RAGE on lung physiology 
To investigate the effect of RAGE on general lung tissue dynamics, pulmonary function testing 
was performed on the RAGE-/- mice and wild-type mice with and without exposure to chronic 
cigarette smoke. Tissue elastance (H) acts as a measure of energy conservation in the lung tissue, 
a decrease in H as seen in emphysema would imply a decrease in capacity of the lung to return to 
its original form on removal of external distending forces.  Wild-type smoke exposed mice 
showed a significant decrease (p-value=0.048) in lung tissue elastance (H) in a dose-dependent 
manner to methacholine challenge when compared to their room-air exposed controls (Figure 2, 
panel A). Although emphysema was too mild to detect differences in tissue elastance (H) at 
baseline, addition of methacholine brought out significantly reduced elasticity with smoke 
exposure, which correlated with the significantly enlarged alveoli observed in these mice on 
morphometric analysis (Figure 1E & Table 1).  
RAGE deficient mice at baseline did not display any difference in tissue elastance (H) 
irrespective of their exposure to cigarette smoke or room-air when compared to their wild-type 
counterparts. However, on challenge with 30mg/ml of methacholine the RAGE-/- air-exposed 
mice (Figure 2A) displayed a trend towards decreased tissue elastance (75.29 cmH2O/ml) as 
compared to the air-exposed wild-type mice (101.65 cmH2O/ml). Chronic smoke exposure in 
RAGE deficient mice did not lead to any reduction in lung tissue elastance compared to their 
room-air exposed RAGE-/- control mice. RAGE-/- mice irrespective of their exposure to 
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cigarette smoke or room-air had similar changes in H when compared with wild-type chronic 
smoke exposed mice on bronchodialation. While differences in H were observed with smoke 
exposure, we did not appreciate any changes in dynamic compliance, C (Figure 2B). 
 
 
Figure 2: Smoke-exposed RAGE-/- mice show no reduction in lung tissue elastance on bronchocontriction 
when compared to their air-exposed controls 
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Respiratory mechanics of RAGE-/- mice and wild type mice (n=5-10 mice per strain per treatment group) 
previously exposed to cigarette smoke or room air was assessed using a mechanical ventilator (Flexivent) as 
described in the methods section. Panel A indicates a significant reduction in lung tissue elastance in wild type 
smokers () as compared to the air-exposed controls () on bronchocontriction. However, RAGE-/- mice show no 
reduction in lung tissue elastance (H) on cigarette smoke exposure () (or methacholine challenge) compared to 
their controls (). Panel B-Dynamic lung compliance (C) was not significantly altered on methacholine challenge 
in either mouse model irrespective of cigarette smoke exposure.  * P-value < 0.05 indicates statistical significance.                    
  
2.3.3 Cigarette smoke induced apoptosis is RAGE-dependent on chronic smoke exposure 
Alveolar endothelial and epithelial apoptosis is well characterized in cigarette smoke-induced 
COPD that correlates with the loss of alveolar tissue [95]. To investigate the role of RAGE in 
mediating cellular damage in response to cigarette smoke exposure, total lung homogenates from 
RAGE-/- and wild-type mice were probed for caspase-3 as a marker of apoptosis. Concurrent 
with previous studies, cleavage of caspase-3 was elevated in the wild-type smoke-exposed mice 
when compared to their air-exposed controls. Western blotting for caspase-3 indicated reduction 
in cleaved caspase-3 (17,19kDAa) levels in the RAGE-/- smokers compared with wild-type 
smokers (Figure 3). The pro-caspase (35kDa) levels were similar between the wild type and 
RAGE-/- mice irrespective of their exposure to cigarette smoke or room air (Figure 3). Wild-type 
mice exposed to cigarette smoke had elevated cleaved caspase-3 levels when compared to their 
air-exposed controls. In the absence of RAGE, no alteration in cleaved caspase-3 levels was 
observed in total lung homogenates from cigarette smoke exposed and air exposed mice. 
Subsequent repetition of this blot confirmed these observations in an n=6 per strain per treatment 
group. 
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 Consistent with morphometry and physiology these findings suggest protection from 
cellular damage in response to cigarette smoke mediated injury in RAGE-/- mice, leading to a 
decreased loss of the underlying matrix and manifesting in significant protection from cigarette 
smoke induced emphysema. 
 
Figure 3: RAGE expression contributes to apoptosis on chronic cigarette smoke exposure. 
Lung homogenates (50µg per well) harvested from RAGE-/- and wild-type mice (n=2/strain/treatment) exposed to 
chronic cigarette smoke were separated by an SDS-PAGE and immunoblotted for caspase-3. Pro-caspase 3 (35kDa) 
levels were unaltered irrespective of the exposure of cigarette smoke or room air in both RAGE-/- and wild type 
mice. GAPDH (37kda) was used as an internal control. Cigarette smoke exposure led to caspase-3 cleavage in wild 
type mice, but not RAGE-/- mice. 
2.3.4 Impaired neutrophil recruitment observed in RAGE -/- mice on acute cigarette 
smoke exposure. 
Emphysema results from inflammatory cell-mediated elastolysis. Moreover RAGE has been 
shown to mediate the adhesion and recruitment of inflammatory cells (Chakavis T, 2003 & 
2004). Upon exposure to cigarette smoke, neutrophils are recruited within hours and return to 
normal within 24 hours. Macrophages and lymphocytes are not as acutely responsive but appear 
to accumulate over time.  Following six months of cigarette smoke exposure we observed 
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macrophage accumulation. However, we did not detect any differences in chronic macrophage 
exposure or MMP-12 production (unpublished data) in the RAGE-/- mice on long-term smoke 
exposure. 
Acute smoke exposure led to no change in total BALF cell counts (Figure 4A), although 
there was a significant neutrophil accumulation in wild-type mice but not in RAGE-/- mice 
(Figure 4B). Specifically, at four hours post-acute smoke exposure wild-type mice showed an 
eight-fold increase (p-value= 0.018) in neutrophils recruited when compared to their room-air 
exposed controls (Figure 4B). The macrophage or monocyte and lymphocyte counts were 
unaltered at 4 hours post-acute smoke exposure in the wild-type mice as compared to their room-
air exposed controls (Figure 4C and D). In contrast, the RAGE-/- mice showed no significant 
increase (p-value=0.475) in neutrophils at 4 hours post-smoke exposure (Figure 4B) compared to 
their room-air exposed controls. There was no significant difference in the macrophage, 
monocyte and lymphocyte counts from the BALF of RAGE-/- mice at 4 hours post-acute smoke 
exposure when compared to their air-exposed controls (Figure 4, panels C and D). These 
observations indicate the critical involvement of RAGE in the early recruitment of neutrophils on 
acute smoke exposure and in emphysema. 
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Figure 4: RAGE mediates early recruitment of neutrophils in response to acute cigarette smoke exposure 
The bronchoalveolar lavage fluid (BALF) collected from the lungs of RAGE-/- (grey bars) and wildtype (black bars) 
mice (n=8-15 per strain per group) was used to stain and quantify cells that had migrated into the fluid lining the 
alveoli. Panel A indicates the total cell counts obtained from the BALF of the different treatment groups on acute 
cigarette smoke exposure. RAGE-/- mice display significantly reduced recruitment of neutrophils at 4 hours post- 
smoke exposure as compared to their wild-type counterparts (Panel B). There was no significant alteration observed 
in the number of macrophages or monocytes (Panel C) and lymphocytes (Panel D) recruited in either the RAGE-/- 
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or wild-type mice at 4 hours post-acute smoke exposure. (* p-value ≤0.05 indicating statistical significance). The 
error bars indicate the standard error mean (SEM) within each group/treatment/time point 
2.4 RAGE-DISCUSSION 
Upon long-term exposure to cigarette smoke, despite having enlarged airspaces at baseline, 
RAGE-/- mice did not develop significant airspace enlargement compared to RAGE+/+ mice. 
Protection from smoke-induced emphysema in RAGE-/- mice was based upon morphometry 
with less increase in airspace dimensions, physiology with less loss of elastance, and less cellular 
damage and apoptosis. Mechanistically, this was related to impaired neutrophil recruitment in the 
absence of RAGE. 
   
Enlarged alveolar dimensions at baseline in RAGE-/- mice suggest a role for RAGE during 
alveolar development. RAGE is expressed highly on alveolar type-I (AT-I) cells under normal 
conditions [166, 167] and is a marker of terminal differentiation on these cells [139]; hence the 
absence of RAGE may contribute to defective differentiation of the alveolar epithelial cells in the 
lung parenchyma. Of note, mouse models that over-express human RAGE have been described 
to have poor alveolar septation during post-natal development [168]. These findings combined 
with our observation of enlarged airspaces in the RAGE-/- mice (Figure 2C) point toward a 
requirement for RAGE in normal alveolar development.  
 
RAGE has been implicated as having a role in COPD. Clinical studies demonstrated increased 
staining for advanced glycation end products (AGE) and RAGE in lung sections from COPD 
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patients with an FEV1 <80% predicted, this was equivalent to GOLD stage 2-4 [158]. 
Additionally, this increased intensity of RAGE staining was significantly elevated in the alveolar 
walls when compared to the airways. Further, lower plasma levels of soluble RAGE (sRAGE) 
correlated with increased severity of emphysema in COPD patients when compared to controls 
who lacked airflow obstruction [160]. These findings were corroborated by observations in a 
larger COPD patient cohort [169].  In vitro studies performed using a rat alveolar type-I cell line 
(R3/1), human alveolar type-II cell line (A549) and a murine macrophage-like cell line 
(RAW246.7) showed upregulated expression of RAGE and RAGE ligands upon exposure to 
cigarette smoke extract (CSE) [161]. In this study we directly confirmed a role for RAGE in the 
pathogenesis of emphysema by using RAGE deficient mice exposed to chronic cigarette smoke 
and show that they are significantly protected from smoke induced airspace enlargement. 
 
Inflammation associated destruction of lung tissue, particularly elastin, has been the basis for the 
pathogenesis of emphysema [90, 170, 171]. The elastase: antielastase hypothesis has stood the 
test of time for over 50 years [19, 88, 172, 173].  With respect to inflammation, acute cigarette 
smoke exposure leads to transient recruitment of the short-lived neutrophils to the lung. 
Recruitment and loss within 24 hours is repeated throughout our 6-month smoking study. Hence, 
despite representing a small percentage of the total cells recovered by BAL, there is a large 
contribution of neutrophil burden elicited by smoking.  Upon prolonged smoke exposure, longer-
lived lymphocytes and macrophages accumulate in the lung.   
Both neutrophils and macrophages interact to promote emphysema, largely through their 
elastases: neutrophil elastase (NE), macrophage elastase (MMP-12) and perhaps MMP-9 
expressed by both neutrophils and macrophages [121].  In our study, RAGE deficiency impairs 
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neutrophil accumulation but not macrophage numbers and MMP-12 content (not shown). In this 
study, RAGE appears to be essential for neutrophil recruitment demonstrated by the fact that 
RAGE-/- mice have only ~17% the neutrophils in response to cigarette smoke exposure than 
wild-type mice do, which corresponded to ~78% protection against emphysema. Hence, these 
studies further support the importance of neutrophils in emphysema and suggest that RAGE is 
involved in cigarette smoke induced recruitment of neutrophils into the lung. 
 
RAGE when engaged by its ligands has been shown to activate intracellular NF-κB mediated 
chemokine/cytokine transcription, thereby perpetuating inflammatory cell recruitment in other 
acute and chronic inflammatory disease models [174-177].  In addition AGE-RAGE signaling 
may up-regulate the expression of several adhesion molecules through NF-κB activation namely 
E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 
(VCAM-1) specifically on endothelial cells [178, 179]. In fact, RAGE has been identified as a 
counter-receptor for the leukocyte β2 Integrin Mac-1 facilitating its adhesion and recruitment 
across the vasculature [180].  
We now extend the importance of RAGE to cigarette smoke related neutrophil but not 
macrophage recruitment. We tested many pro and anti-inflammatory cytokines and chemokines 
in our model but we were unable to detect differences in their circulating levels (not shown). 
Either the changes were too subtle to detect, or alternative mechanisms exist in this model that 
require further investigation. 
 
The contribution of extracellular matrix destruction versus cellular apoptosis has been debated. 
Clearly loss of alveolar tissue and consequently enlarged airspaces requires both the loss of 
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structural cells and extracellular matrix (ECM). Whether the events are separate or one leads to 
the other (and which one initiates) is less clear. However it is plausible that the loss of ECM 
leads to anoikis (death following matrix detachment). Alternatively, cell death could lead to 
inflammation. In this study, we observed increased apoptosis in the RAGE+/+ mice exposed to 6 
months cigarette smoke that correlated with emphysema. We interpret this to confirm our 
emphysema phenotype; although this observation sheds no additional light on the mechanism. 
This is consistent with previous studies have also found a role for RAGE in promoting apoptosis 
in other lung models [162].   
 
Lung physiology of the RAGE+/+ mice show a significant decrease in lung tissue elastance on 
methacholine challenge mirroring the phenotype observed with chronic cigarette smoke 
exposure. In the absence of RAGE we find that there was no loss of lung tissue elastance with 
methacholine challenge (Figure 2A), this finding correlated with the partial protective phenotype 
observed on chord length quantification in the RAGE-/- mice (Table 1). Together, these 
observations suggest that loss of RAGE, despite leading to abnormal alveolar development, 
confers protection from further airspace enlargement in response to cigarette smoking. 
   
The current study adds RAGE to a growing list of mediators of emphysema and confirms the 
importance of neutrophil recruitment. Further understanding of mechanisms of neutrophil 
recruitment could lead to novel therapy that is badly needed for this devastating and common 
disease, although cigarette-smoking cessation remains most important. As the era of precision 
medicine arrives, RAGE polymorphisms could also be a factor that identifies smokers who are 
either resistant or susceptible to COPD [159]. Single nucleotide polymorphisms (SNPs) in the 
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minor allele (T allele) within exon 3 of RAGE gene, which converts a glycine at the 82nd position 
into serine (G82S) present within the ligand-binding pocket increases affinity for AGE ligands 
and enhances its ligand binding function [181, 182]. A recent clinical study in a Chinese 
population suggested that smokers with the G82S polymorphism in their RAGE gene had an 
elevated risk of developing COPD[183]. This finding along with future studies holds the promise 
of better evaluation of individual susceptibilities to this disease and its possible prevention. 
2.5 RAGE- FUTURE DIRECTIONS 
The results of this study demonstrate that RAGE is required for progression of emphysema in 
mice. The enlargement of airspaces observed in the RAGE deficient mice on exposure to room-
air, additionally suggest its involvement in the development of the alveolar compartment. 
Expression of RAGE in other organ systems that undergo branching morphogenesis such as the 
kidney and neurite outgrowth post-peripheral nerve injury confirm its critical function in organ 
development and repair [184, 185]. Furthermore, moderate over-expression of human RAGE in 
mice during post-natal alveolar development demonstrated its involvement in secondary alveolar 
septation resulting in enlarged airspaces [168]. This observation was corroborated by a different 
group that over-expressed mouse RAGE in a doxycycline inducible mouse model that showed 
similar alveolar enlargement with poorly fused basement membrane and decreased collagen 
deposition [186]. RAGE expression is significantly elevated in the lung during post-natal 
alveologenesis in AT-I cells at post-natal day-4 (PN4) through PN10. Moreover, its expression 
was positively regulated by early growth response gene-1 (Egr-1) and negatively regulated by 
thyroid transcription factor-1 (TTF-1) [161]. Although our findings along with other published 
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studies highlight a role for RAGE in alveolar development, we still do not understand the exact 
role of this receptor during lung development and adult lung homeostasis. Future studies would 
involve trying to dissect molecules lying downstream or upstream of RAGE that facilitate the 
process of alveolarization. In the RAGE-/- mice, one could begin by investigating Egr-1 and 
TTF-1 expression to check for any differences in levels of expression during post-natal alveolar 
septation. 
Lung fibroblasts mainly synthesize elastin during lung development [187, 188]. In vitro 
experiments involving the over-expression of mouse RAGE or sRAGE in mouse lung fibroblasts 
indicated an elevation in elastin mRNA synthesis [189]. Since AT-I epithelial cells are the 
primary source of RAGE expression, a potential direction to investigate is if the loss of RAGE 
expression especially on the structural cells in RAGE deficient mice influences the amount of 
elastin synthesized by the alveolar fibroblasts especially during alveolar development. By 
measuring desmosine and isodesmosine levels (a measure of elastin) in lung tissue [190] from 
RAGE deficient mice and comparing it to their wild-type (RAGE+/+) controls, we may attempt 
to explain the enlarged airspaces observed in the room-air exposed RAGE-/- mice (Figure 1C) in 
our chronic smoke experiments. 
Toll-like receptor-4 (TLR4) has been linked with RAGE to signal through similar 
pathways leading to inflammation in patients with type-II diabetes [191]. Subsequently, TLR4 
deficient mice have been shown to elevate NADPH oxidase (NOX3) expression in their lungs 
leading to an increase in oxidant activity [192]. Investigation of NOX3 expression in the absence 
of RAGE expression, using RAGE-/- mice that are exposed to cigarette smoke and comparing 
them to their room air exposed controls may provide some insight into their oxidative stress 
bearing capacity. Additionally, RAGE and TLR4 share several common ligands such as HMGB1 
 47 
[128, 133], S100A8/A9 [193, 194] and lipopolysaccaride (LPS)[195, 196] which may mediate 
their effects through TLR4 in the absence of RAGE expression. Hence it may be worthwhile 
investigating if cigarette smoke induced deregulation of RAGE ligand expression may mediate 
some or none of their effects through alternate pathways, namely TLR4 mediated signaling. One 
way of studying this could be through exogenous administration of RAGE ligands such as 
recombinant HMGB1 into RAGE-/- mice and monitoring their inflammatory response through 
analysis of their bronchoalveolar lavage fluid (BALF). Elevated HMGB1 has been suggested to 
mediate neutrophilic inflammation albeit in asthma [197]. The results of this study will further 
indicate if elevated levels of HMGB1 or any other RAGE ligand is capable of initiating an 
inflammatory response independent of RAGE. An alternate investigation may incorporate using 
a double knockout mouse deficient for TLR4 and RAGE, to study the effect of cigarette smoke 
induced HMGB1 accumulation [198] on the cells mediating innate immunity. 
A number of studies correlate the levels of sRAGE to the extent of disease, however the 
exact mechanisms by which sRAGE levels are altered are not clear. Reduced levels of systemic 
sRAGE were reported in a group of stable COPD patients when compared to their healthy 
controls and further reduction in sRAGE levels was reported in those patients during acute 
COPD exacerbations [169]. These observations were confirmed later by a different research 
group in a larger cohort of COPD subjects who observed greater loss in pulmonary function with 
reduced circulating levels of soluble RAGE [160]. Despite soluble RAGE being largely 
attributed to have an antagonistic function to membrane bound RAGE [199], there are studies 
that indicate that sRAGE may have agonist functions as well [200, 201]. The effect exerted by 
sRAGE may depend on the levels of RAGE ligands present in the context of normal lung 
homeostasis or injury. Therefore, one approach could be to investigate the contribution of 
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sRAGE in the context of cigarette smoke induced injury in RAGE-/- mice. Since RAGE-/- mice 
show partial protection from chronic cigarette smoke exposure, one would expect that if sRAGE 
played an antagonistic function that the RAGE-/- mice would show greater protection on 
cigarette smoke exposure. On the other hand, if sRAGE plays a more agonistic role we would 
expect that the RAGE-/- mice do much worse on cigarette smoke exposure. By understanding 
the role of sRAGE in the context of emphysema, we can aim to translate our findings to potential 
therapeutic solutions. A novel large molecule RAGE inhibitor (TTP4000) is currently in the 
clinical developmental phase for treating Alzheimer’s disease (Transtech Pharma Inc.) and could 
potentially find therapeutic utility in chronic lung diseases in the near future. The realization of 
which would evidently need for us to have a better understanding of the mechanisms by which 
different RAGE ligands specifically bind and signal through RAGE in the context of disease. 
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3.0  A DISTAL BRONCHIAL PROGENITOR CELL (DBPC) POPULATION 
CONTRIBUTES TO ALVEOLAR REPAIR IN EMPHYSEMA USING MOUSE 
MODELS 
Understanding cellular events that initiate endogenous reparative mechanisms and the reasons 
for their failure in progressive inflammatory diseases such as emphysema will provide much 
needed insight as to how we may one day better treat this disease. Alveolar repair is a complex 
process with multiple components that require coordination to bring functionality to the alveolus. 
These include maintaining an intact basement membrane, repopulation of damaged alveolar 
epithelium and building tight junctions between the epithelial and endothelial layers to facilitate 
gaseous exchange. The current study will focus on understanding the role of a distal bronchial 
epithelial (progenitor) cell towards alveolar repair, which forms a component of this multi-step 
reparative process.  
To study the contribution to alveolar repopulation of this previously identified distal 
bronchial progenitor cell, we developed a transgenic mouse line that enabled us to lineage trace 
these cells and their movement from the distal bronchi into the surrounding alveolar epithelium 
in the context of injury. Transgenic mice were exposed to cigarette smoke or intratracheal PPE 
and their lungs were analyzed at the end of the experiment to monitor the contribution of these 
distal bronchial progenitor cells (DBPCs). Our observations indicate a significant contribution of 
the DBPCs in the alveolar compartment of the lung post-injury with increased migration and 
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potential repopulation of alveolar epithelial cells. Further these observations were validated using 
a knock-in mouse model, which confirmed our findings in the initially developed transgenic 
mouse model.  
Overall our findings point towards a significant contribution of the DBPC population in 
the alveolar compartment amplified by injury and their capacity to repair the alveolar epithelial 
cell population. 
3.1 DBPC- BACKGROUND 
3.1.1 Epithelial cell populations in the lung 
Mouse lungs are comprised of a variety of epithelial cell populations. The trachea and proximal 
airways are typically lined with basal cells, ciliated cells, goblet cells and small numbers of 
neuroendocine cells. The distal and terminal bronchi are composed mostly of non-cilated 
columnar Clara cells [202]. The alveolar compartment of the lung is mainly comprised of two 
types of cells alveolar type-I (AT-I) and alveolar type-II (AT-II) cells [203].  AT-I epithelial cells 
make up approximately 95% of the alveolar compartment of the lung. AT-I cells and endothelial 
cells joined by a fused basement membrane form the air-blood barrier across which gaseous 
exchange occurs.  AT-I cells are known to mainly regulate alveolar fluid balance and surfactant 
protein secretion by alveolar type-II (AT-II) cells in the lung [204-207]. On the other hand, AT-
II epithelial cells populate the remaining ~5% of the alveolar epithelium. These cells are cuboidal 
and are interspersed between AT-I cells, commonly characterized by lamellar bodies and 
microvilli on their apical surface [203]. AT-II cells are involved in the production, secretion and 
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resorption of pulmonary surfactants in response to stretch vital in providing the required surface 
tension that prevents the alveoli from collapsing [208]. 
3.1.2 Alveolar repair in normal and emphysematous lungs 
The general assumption has been that once the alveolus is damaged or fails to develop properly 
there is rarely any successful spontaneous attempt at alveolar repair or regeneration of the lost 
alveoli. We continue to explore and try to understand the role of putative endogenous progenitors 
that aid in maintaining this fragile alveolar compartment that is exposed to external and internal 
stresses as well all fend us against toxic insults on a daily basis.   
Evidence for alveolar repair mechanisms in rodent models sheds light on possible contributors of 
such endogenous repair. Adult mice that were ovariectomized displayed lesser surface area and 
larger alveoli when compared to their controls. After 3 weeks of estrogen treatment these 
ovariectomized mice showed alveolar regeneration [209]. Other studies involving calorie 
restriction of the diets of adult rats showed changes in the lung as early as 2 hours similar to 
those seen during the activation of apoptosis. However, by the end of 72 hours the rats showed 
significant alveolar loss. After 15 days on the calorie-restricted diet, when the rats were returned 
to a calorie-enriched diet they displayed alveolar regeneration within a span of 72 hours [210]. 
These studies were instrumental in providing insight into regenerative cues that were capable of 
inducing alveolar remodeling. 
Elastin fibers are one of the most complicated to repair as they are molecularly complex, 
have slow turnover and require a number of helper proteins to facilitate its assembly [170]. In the 
context of emphysema, inflammatory cell secrete proteases that attack these long-lived fibers and 
cause their degradation. The elastin fragments generated by this elastolytic activity further serve 
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to recruit more inflammatory cells furthering the damage [23]. Tropoelastin monomers secreted 
by myofibroblasts form the basal unit; these monomers aggregate in presence of fibrils and are 
cross-linked by lysyl oxidase. These larger conglomerates of elastin then leave the cell surface 
and fuse with microfibrils in the extracellular space (composed of fibrillins). Once associated 
with the microfibrils, these elastin aggregates coalesce forming even larger aggregates. The final 
maturation process of the elastin fibers involves cross-linking of newly formed elastin aggregates 
with the microfibrils while removing older fibers. This multi-step proposed model of elastin 
assembly demands both extensive energy and cellular resources, which are precious to the cell. 
In addition when levels of functional elastin are below a critical threshold, attempts at repair after 
injury become unproductive and can lead to further progression of emphysema [211]. 
Retinoids, a vitamin A derivative, have been shown to be essential to the development of 
many organs including the lung. Retinoids are stored as retinyl esters in lipid-laden fibroblasts in 
the lung, which is its second largest storage site [212]. All-trans retinoic acid (ATRA), a 
biologically active form of retinoids, has been shown to regulate elastin in the lung [213]. 
Further, when ATRA was supplemented post-natally during alveolar septation in rats there was 
an increase in numbers of alveoli but did not show any increase in alveolar surface area [214]. To 
evaluate the regenerative potential of ATRA in the context of disease, adult rats were 
intratracheally treated with elastase to induce emphysema and subsequently treated with ATRA. 
ATRA was found to restore the damaged alveoli in these rats and reversed pathological features 
of airspace enlargement observed [215]. Thus strengthening the potential role of ATRA as an 
exogenous agent inducing lung regeneration in animal models. Clinical studies performed using 
ATRA in patients with emphysema showed no changes in outcome measures with a delayed 
improvement in gas exchanged at a higher dose of ATRA [216, 217]. 
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3-hydroxy 3-methyl glutaryl coenzyme A reductase inhibitor (simvastatin) was used to 
treat elastase-exposed mice and showed reversal of emphysema (reduced chord length) and an 
increase in proliferating alveolar epithelial cells [218]. Other studies have elucidated the role of 
simvastatin in blocking endothelial smooth muscle cell proliferation and in blocking vascular 
injury [219]. A number of growth factors have been assessed for their role in alveolar repair. 
Keratinocyte growth factor (KGF or fibroblast growth factor-7, FGF-7) has been implicated in 
alveologenesis, however when used to treat rats with elastase-induced emphysema it was unable 
to reverse the damage incurred. Pre-treatment with KGF nevertheless provided protection from 
subsequent elastase induced alveolar injury [220]. Hepatocyte growth factor (HGF), known to be 
a potent mitogen for alveolar type-II epithelial cells when transfected into rats with elastase 
induced emphysema displayed an increase in alveolar cell counts [221]. Mice treated with 
intranasal HGF showed reversal of elastase-induced emphysema [222]. The potential of HGF in 
treating human emphysema is yet to be assessed. 
 
3.1.3 Pulmonary epithelial progenitor cell populations 
Injury models have been widely helpful to identify and study various epithelial stem cell niches 
in the lung [223]. A population of cells (basal cells) found in the trachea and proximal airways 
has been shown to be resistant to injury caused by exposure to detergent polidocanol or sulfur 
dioxide exposure [224]. These basal cells have been shown to be a progenitor cell population for 
ciliated cells, clara cells and secretory cells lining the airways [225]. Bleomycin, a 
chemotherapeutic agent that damages several cell types in the alveolar compartment, led to the 
identification of some resistant AT-II cells capable of replicating and differentiating into AT-I 
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epithelial cells hence repopulating the alveolus [226]. The naphthalene injury model aided in the 
identification of two clara cell secretory protein (CCSP) expressing progenitor cell populations in 
the proximal and distal airways; one resistant population that is closely associated with 
neuroendocrine bodies (NEB) in the proximal airways [227-229] and the other resistant 
population located in the terminal bronchial duct junction [230]. Bronchoalveolar stem cells 
(BASCs) have been shown to repopulate Clara cells on napthalene injury of distal airways and 
AT-II cells on bleomycin injury of the alveoli [231, 232]. Therefore by recognizing the 
molecular signals that activate these progenitor populations to proliferate and differentiate and 
other inhibitory signals that block this reparative function in the context of injury, we can hope to 
regenerate the damaged alveolus in emphysema. 
3.1.4 Potential involvement of other cell lineages towards lung epithelial repair 
Embyronic stem cells (ESCs) isolated from the inner cell mass of a blastocyst (from a fertilized 
egg) has the potential to give rise the cells types belonging to all three germ layers 
(pluripotency), namely ectoderm, mesoderm and endoderm. These ESCs may be cultured 
indefinitely, maintain their pluripotency and can be induced to differentiate into a specific cell 
type based on signaling molecules (cues) supplemented in their growth media. ESCs both from 
human and mouse have been successfully differentiated into alveolar type-II epithelial cells with 
lamellar bodies and surfactant protein production [233-236]. Mouse ESCs were shown to yield in 
greater endodermal differentiation in presence of activin and Wnt3a, than activin alone. On 
further treatment with fibroblast growth factor -2 (FGF-2) these cells began to express surfactant 
proteins and developed lamellar bodies characteristic of mature AT-II cells [237]. The challenge 
however in using ESCs for transplants/treatment remains the generation of pure differentiated 
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AT-II cells populations, without any undifferentiated ESCs, which can give rise to teratomas. 
The second challenge is an ethical one that involves generation and use of human ESCs. 
The induced pluripotent stem cell (iPSC) technology has enabled us to overcome some of 
the limitations discussed earlier in using ESCs. iPSCs may be derived from an adult somatic 
cells, by tranfecting them with 4 factors (Klf4, Sox2, Oct3/4 and c-Myc) previously described to 
re-program them into a pluripotent stem cell. Since iPSCs may be derived from an adult somatic 
cell, for example a skin cell from a patient with A1AT deficiency, it can then be reprogrammed 
into AT-II cells capable of expressing A1AT and transplanted back into the patient without the 
issue of immune rejection. Recent studies conducted using mouse fibroblast-derived iPSCs 
cultured in activin-A supplemented small airway growth media over 14 days, displayed 
differentiation into SP-C expressing AT-II epithelial cells and AQP-5 expressing AT-I cells 
[238]. Mouse models of endotoxin mediated acute lung injury demonstrated significant 
physiological improvement complimented by reduced levels of NF-κB and neutrophils in their 
lungs on intravenous treatment with mouse iPSCs [239]. Although iPSCs have generated a lot of 
interest and present potential use in the field of lung regeneration, their clinical safety and 
efficacy as a therapeutic are yet to be ascertained.  
Other cell types thought to have a reparative role in the lung include bone marrow 
derived cells injected intra-venously shown to migrate and engraft to the lung upon lung injury 
[240]. Although some of these studies have suggested that these cells are capable of 
differentiating to AT-I and AT-II cells within the lung [241], these results have been widely 
debated and hence very controversial [242, 243]. Further examination of lung histology from 
mice transplanted with eGFP tagged bone marrow cells indicated over-lapping fluorescence 
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intensities of AT-II SP-C+ cells with e-GFP positive bone marrow derived cells by 
deconvolution confocal microscopy [242]. 
Bone marrow derived stem cells are of two types hematopoietic stem cells (HSCs) 
capable of giving rise to the different blood cell types and bone marrow derived mesenchymal 
stem cells (BMDMSCs). The BMDMSCs have been described as a potential adult progenitor cell 
capable of homing to the lung under acute injury and giving rise to AT-I cells [244-246]. Other 
investigations have shown an increase in bone marrow derived cells in the lungs of elastase-
injured mice post-treatment with granulocyte colony stimulating factor (G-CSF) [247]. Several 
studies have elucidated the contribution of these cells towards immunomodulation via 
suppression of pro-inflammatory factors and release of various growth factors in different injury 
models [244, 248-250]. The direct contribution of BMDMSCs towards repopulating the alveolar 
epithelium is still largely unclear, however they do appear to engraft in the lung in much smaller 
numbers (~1-2%) than initially described [251]. 
3.1.5 Bioengineering lung tissue ex vivo 
While the intra-tracheal delivery of iPSCs holds considerable promise as cell-based therapy, one 
of the main challenges has remained the availability of bio-active lung scaffold that the epithelial 
cells can engraft on, form tight junctions between one another and functionally communicate 
with the underlying vasculature. Biologically engineered lung scaffolds that can support lung 
progenitor cells to replace lost/damaged regions of the lung are an alluring prospect and have 
generated a lot of interest in the past decade. Several groups have explored the use of synthetic 
and naturally derived scaffolds seeded with different adult lung epithelial and progenitor 
populations[252-254]. The progenitor cells populations seeded on these biological scaffolds 
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showed engraftment, differentiation into CC10 expressing Clara cells as well as SP-C expressing 
AT-II cells and development of distal airway like structures. The first successful clinical 
procedure involved treating a 30-year old woman with bronchomalacia (tracheal-defect) with a 
tracheal graft seeded with the patient’s own cells. The scaffold used involved de-cellularizing 
cadaveric trachea, on one side of which the patients own bronchial epithelial cells were seeded 
and on the other MSC derived chondrocytes [255]. The bio-engineered tissue seems to have 
restored lost function in the patient, yet long-term follow-ups will determine if the procedure 
provided a life-long solution. 
A more recent study conducted in rats, demonstrated this exciting potential of bio-
engineered lung. The study involved decellularizing rat lungs in a bioreactor followed by 
transplanting microvascular lung endothelial cells into the pulmonary artery and pulmonary 
epithelial cells into the lung. Once the cells had seeded and repopulated the lungs, the 
distribution and phenotype of cells repopulating the vasculature and lung were confirmed by 
immunofluorescence staining. Further the bio-engineered rat lung was transplanted into the left 
lung of 4 rats to show functionality (gas-exchange), structural integrity and vascularization [256]. 
3.2 DBPC- MATERIALS AND METHODS 
3.2.1 Lineage tracing of distal bronchial progenitor cells 
3.2.1.1 Transgenic mouse model- CC10-Cre; ROSA-LacZ 
A transgenic mouse line that stably expresses Cre recombinase (with SV40 promoter, intronic 
elements and polyA tail) under the rat CC10 promoter (generous gift of Dr. Jeffrey Whitsett) was 
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generated in our laboratory [257]. This mouse line was then bred with a Rosa 26 reporter mouse 
line that consisted of a constitutively active Rosa 26 promoter followed by a loxP-STOP-loxP 
codon that prevented active LacZ expression. The resultant progeny expressed Cre recombinase 
specifically in all CC10 positive cells, which cleaved the Lox-P sites flanking the STOP codon 
downstream of the constitutively active Rosa26 promoter and initiated transcription of LacZ. 
Consequently, the daughter cells of this parent (LacZ+ CC10+) cell then expressed LacZ 
irrespective of their CC10 expression status allowing one to trace their movement from their 
niche. LacZ transcription further led to the synthesis of β-galactosidase (β-gal) enzyme, which 
when exposed to 5- bromo-4chloro-3indolyl β-D-galactopyranoside (X-gal) substrate, produced 
an insoluble blue precipitate used to stain the lineage tagged daughter cells. These transgenic 
mice generated from crossing the ratCC10 Cre mouse with the Rosa26-LacZ reporter mice have 
been termed as CC10-Cre; ROSA-LacZ mice. 
 
 
 
 
 
 
 
 
 
Figure 5: Lineage tracing distal bronchial epithelial cells 
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A schematic illustrating the breeding strategy used in the generation of CC10-Cre; Rosa26-LacZ progeny for 
lineage tracing DBPCs. A Rosa26-LacZ reporter mouse line was bred with a transgenic mouse line carrying 
Cre recombinase under the control of 2.4kb Rat CC10 promoter. 
3.2.1.2 Cre specificity in the CC10-Cre; ROSA-LacZ transgenic mouse 
We evaluated the specificity of ratCC10 promoter expression in the lungs of mice post-PPE 
induced injury/ PBS treated controls by immunofluorescence staining for ratCC10 on X-gal 
stained lung sections. Visualization of the stained sections indicated that ratCC10 expression was 
limited to β-Gal+ cells in the airways and not in the alveolar space both in the PPE treated mice 
and their controls that got treated with PBS (Appendix A, Figure 16). The protocol is detailed 
below under “3.2.7 Immunofluorescence staining” subsection. 
Additionally to accertain that Cre recombinase expression was selective to the airways, 
we immunofluorescence stained lung sections from PPE exposed transgenic mice for Cre. The 
stained sections on visualization by fluorescence microscopy confirmed Cre expression was 
specific to the airways in both the PPE as well as PBS treatment mice (Appendix A, Figure 15). 
3.2.1.3 Constitutive knock-in mouse model- CC10-iCre; ROSA-LacZ 
To completely rule out the possibility that there was any leakiness in Cre expression that was 
below our threshold of detection (as shown in Appendix A, Figure 15 & 16), we chose to use a 
constitutive knock-in mouse model to lineage trace the DBPCs. This knock-in mouse model with 
an improved version of Cre recombinase (iCre) was characterized by early embryonic expression 
and deeper penetration, which was knocked-in under the endogenous and constitutively active 
CC10 promoter (CC10-iCre) (obtained from Jackson laboratories).  Dr. Francesco Demayo’s 
group initially developed the CC10-iCre mouse (Li, Cho et al. 2008), which was later crossed 
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with a lipocalin2-loxP (LCN2-LoxP) mouse (Dr.Yvonne Chan at the University of Pittsburgh) 
and the progeny (CC10-iCre; LCN2-LoxP) banked at Jackson laboratories.  These CC10-iCre; 
LCN2-LoxP mice were on a C57BL/6J background and then crossed with the Rosa26 reporter – 
LacZ mice (ROSA-LacZ) described earlier. The resultant progeny were genotyped to check for 
desired expression of Cre recombinase, Rosa26 reporter and the wild type lipocalin-2 gene. The 
mice with the appropriate genotype were termed as CC10-iCre; ROSA-LacZ mice. 
3.2.2 Murine models of Emphysema 
3.2.2.1 Porcine pancreatic elastase (PPE) model 
The porcine pancreatic elastase (PPE) model is a well-documented model of emphysema. 8-12 
week old female mice were anesthesized with ketamine/xylazine and their tracheas catheterized. 
The experimental group of mice received 1.5 units of PPE administered intra-tracheally and their 
lungs harvested over a course of 21 days. The control mice for the experiment were treated with 
PBS. Within the first 24 hours, the elastase caused direct alveolar damage and emphysema. This 
was followed by a macrophage predominant response over the remaining 20 days through an 
endogenous inflammatory feedback loop leading to extensive endogenous alveolar destruction.  
3.2.2.2  Cigarette smoke model 
The cigarette smoke exposure model has been considered the gold standard model of 
emphysema and involves regular exposure of mice to cigarette smoke over a span of 6 months. 
8-12 week old female mice received smoke from 2 unfiltered 1R5F cigarettes, twice daily, 5 
days a week, over 6 months. This model is characterized by an acute neutrophilic response, 
followed by the accumulation of T cells and macrophages over the next few days. These 
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inflammatory cells further release several elastolytic proteases that cleave the extracellular 
matrix, leading to slow yet progressive loss of the alveolar unit of the lung. The apparatus used 
to deliver the cigarette smoke to the animals has been described previously [8]. The mice 
tolerated 4 cigarettes per day with carboxyhaemoglobin levels under 15% and displayed no 
toxicity. 
3.2.3 Lung tissue processing- X-Gal staining 
Post-cigarette smoke exposure or PPE treatment, the animals were sacrificed at the appropriate 
time points by carbon dioxide narcosis. The chest cavity of the animal was exposed, their 
tracheas cannulated and lungs inflated with 10% normal buffered formalin (10%NBF) under 
25cm H2O pressure. Subsequently the inflated lungs were removed from the chest cavity of the 
mouse and fixed in 10% NBF for an hour at 4°C. The lungs were washed in 1X PBS and stained 
for β-galactosidase (β-gal) activity with X-Gal solution overnight at 37°C. 16-24 hours later, the 
lungs were washed in PBS and fixed for another 24 hours in 10% buffered formalin. These lungs 
were then washed once again in PBS, dehydrated in 70% ethanol, embedded in paraffin and 
sectioned for further analysis. Mid-sagittal sections obtained were stained and used for 
morphometric and histologic analysis. 
3.2.4 β-gal+ lineage tagged cell quantification 
Ten random fields per mouse lung section were selected to image at 20X magnification. The 
lung tissue previous stained with X-Gal for β-gal activity were used to quantify cells staining 
positive in the presence of X-Gal substrate, evident from the insoluble blue colored precipitate 
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produced. The numbers of β-gal+ cells are counted just adjacent to the BADJ junction. 
Additionally, β-gal+ cells that entered the alveolar compartment of the lung were counted and 
averaged to the number of fields counted. The β-gal+ cells in the airways were excluded for this 
purpose on the basis of gross histology. The average numbers of β-gal+ cells in the alveolar 
parenchyma determined were then normalized to the tissue density calculated from the mean 
chord length estimated by morphometry. 
3.2.5 Morphometry 
Ten random fields of modified gills stained sections per animal were captured under 200X 
magnification using NIS-elements program as described earlier (Nikon, Tokyo, Japan). The 
sections were then processed using Scion Image (Scion Corp., Fredrick, MD) avoiding all 
ambiguous areas, airways, smooth muscle and vasculature. The macros program computes the 
average chord length (alveolar diameter) of each alveolus and averages it to the total number of 
alveoli measured to produce a mean chord length value for each specimen. 
3.2.6 Isolation of bronchoalveolar stem cells (BASCs) by fluorescence activated cell 
sorting (FACS) 
Eight adult (> 6 weeks of age) female C57BL/6J mice were used to perform total lung digestion 
to isolate adequate numbers of BASCs. Mice were sacrificed by carbon dioxide narcosis. The 
outer layer of fur followed by the abdominal wall was incised to expose and severe the 
descending renal artery.  Further the diaphragm was punctured to let the lungs collapse into the 
chest cavity and the chest wall exposed. The right ventricle (RV) of the heart was perfused using 
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5-10 mls of PBS. Following perfusion, the trachea was cannulated and 1.5ml of dispase (BD 
Pharmingen) was instilled. The lungs were then harvested and incubated with collagenase/ 
dispase (Roche) and DNaseI (Sigma Aldrich) at 37°C for one hour to allow dissociation of the 
cells from the tissue. The resultant cell suspension was passed through a series of 70μm and 
40μm filters to generate a single-cell suspension. The cells were resuspended in 10% fetal bovine 
serum (FBS) made in PBS, after red blood cell (RBC) lysis was performed.  
Approximately 75-100 million cells in a single cell suspension were blocked with 
CD16/CD32 Fcγ III/II receptor antibody at 1μl/million cells (BD Pharmingen) on ice. The cells 
were subsequently stained with primary antibodies: Sca-1/FITC (BD Pharmingen), CD45-biotin 
(BD Pharmingen) & CD31-biotin-labelled antibodies (BD Pharmingen). After a brief wash to 
remove the primary antibody, the cells were incubated on ice with secondary antibodies 
(Streptavidin-phycoerythrin conjugated; SA-PE) (BD Pharmingen). All antibodies were used at a 
concentration of 1 μl/ million cells. To select for viable cells, DAPI (Molecular Probes) was used 
at a 200μg / ml concentration. The MoFlo-Cytomation machine was used for Fluorescent 
Activated Cell Sorting (FACS) at a low pressure (30Psi). The typical yield ranged approximately 
between 0.5~1.0% Sca-1-FITC positive/CD45-PE negative/PECAM-PE negative cells with 60-
70% viability. The sorted cells were used for isolation of RNA or for cytospins to perform 
immunofluorescence staining. In order to assess purity, sorted cells were fixed with cytofix 
solution (BD Pharmingen), permeablized and stained in a single cell suspension for CC10 and 
SP-C using the same antibodies and concentrations mentioned in the dual immunofluorescence 
staining section (described below). The cells were re-suspended in the hardset mounting media 
with DAPI (Vector Labs), mounted on permafrost slides and cover slips were applied. The 
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BASCs were dual positive for SP-C and CC10 and recovered in a similar manner as described 
above, yielding an approximate purity of 80–90%. 
3.2.7 Immunofluorescence staining 
Lung sections were de-paraffinized and re-hydrated through a series of ethanols. 0.2% Triton-X-
100 in 1X phosphate buffered saline (PBST) was used to permeabilize the sections and blocked 
with 10% normal donkey serum for an hour at room temperature. The sections were further 
incubated with rabbit polyclonal CC10 primary antibody (Millipore) at a 1:1000 dilution and 
goat polyclonal SP-C (Santa Cruz) at a 1:500 dilution overnight at 4°C. Subsequently after 
washing with PBST, the sections were incubated with secondary donkey anti-rabbit Alexa fluoro 
594 antibody (Invitrogen) at a 1:200 dilution and donkey anti-goat Alexa fluoro 488 (Invitrogen) 
antibody at 1:200 dilution in PBS for 30 minutes at 37°C. The sections were washed, stained and 
cover-slipped using the 4', 6-diamidino-2-phenylindole (DAPI) vectastain (Vector labs) kit. 
3.3 DBPC- RESULTS 
3.3.1 Bronchoalveolar stem cells detected at the bronchoalveolar duct junction in normal 
lung tissue 
Naïve C57BL/6J mice were sacrificed, their lungs processed for paraffin embedding and sections 
obtained were dual immunofluorescence stained for two specific cell markers: the Clara cell 
secretory protein -10 (CC10), which is a Clara cell specific marker and surfactant protein-C (SP-
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C) that is an alveolar type-II (AT-II) cell specific marker. In addition, to decipher the nuclei of 
different cell types that populate the lung, the sections were stained with 4', 6-diamidino-2-
phenylindole (DAPI). On imaging by fluorescence microscopy (FM), dual stained lung sections 
(Figure 6, panel A) indicated the presence of cells that stained positive for both CC10 (CC10+) 
and SP-C (SP-C+) at the bronchoalveolar duct junction (BADJ).  
One of the major limitations of FM is the capture of non-specific background that arises 
from the illumination of the entire field by the light source. To overcome the possibility that the 
dual staining observed may be an artifact of this non-specific background, we pursued confocal 
microscopy (CM) imaging that utilizes point illumination in a single field to capture fluorescence 
emission from the tissue section. Imaging by CM confirmed true positive staining for CC10 and 
SP-C on a single cell (BASC) on dual stained lung sections as shown in Figure 6B. Thus, we 
were able to reproducibly detect the presence of BASCs at the BADJ as previously described by 
Tyler Jacks group. 
 
Figure 6: Detection of bronchoalveolar stem cells (BASCs) at the bronchoalveolar duct junction 
Lung sections from naïve C57Bl/6J mice were stained for CC10 in red (Clara specific protein marker), SP-C in 
green (Alveolar type-II cell specific marker) and DAPI in blue (nuclear stain) (A) Fluorescence microscopy imaging 
of dual stained lung sections indicate the presence of dual positive BASCs at the BADJ (as indicated by the arrow) 
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(B) Confocal imaging confirms positive staining for CC10 (in red) and SP-C (in green) in the same cell (additionally 
seen in the magnified section of the image to the bottom right of the panel) 
 
3.3.2 Expansion of BASC population with emphysema associated alveolar injury 
To investigate if alveolar injury had any effect on the BASC population at the bronchoalveolar 
duct junction (BADJ), we exposed 8-12 week old female C57BL/6J mice to porcine pancreatic 
elastase (PPE) by intra-tracheal (IT) delivery while controls were exposed to an equivalent 
volume of phosphate buffered saline (PBS). The mice were sacrificed 1, 3, 5, 7, 10, 14 and 21 
days post-exposure to PPE or PBS, their lungs processed for paraffin embedding and sectioning. 
The lung sections were dual stained for intracellular proteins, CC10 and SP-C and imaged by 
fluorescence microscopy (FM) as described in the methods section. The number of dual positive 
cells (CC10+ and SP-C+) was averaged to the number of BADJs considered per specimen and 
plotted as a function of day’s post-PPE or PBS exposure. As seen in Figure 7A, PPE exposed 
mice exhibited a significant increase (1.5-fold) in the number of dual positive cells at their BADJ 
as early as 7 days post-exposure when compared to their PBS controls.  At 21 days post-PPE 
exposure, a 2-fold increase (p≤0.05) was observed in the numbers of BASCs at the terminal 
BADJ when compared to their 21 day PBS controls (Figure 7A). Together, these findings show 
progressive expansion of the BASC population at the terminal bronchoalveolar duct junction 
(BADJ) with PPE-associated alveolar injury but not in their PBS-exposed counter-parts. 
We examined the expansion of these distal BASCs in the cigarette smoke exposure 
model (gold-standard) of emphysema to confirm our observations in the PPE injury model, for 
this we exposed 8-12 week old female C57BL/6J mice to chronic cigarette smoke or room-air 
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over a period of 3 and 6 months before they were sacrificed. Whole lung isolations were 
performed and single-cell suspensions obtained were stained for cluster of differentiation 31 
(CD31 or PECAM-platelet endothelial cell adhesion molecule), CD45 (hematopoietic cell 
marker) and stem cell antigen-1 (Sca-1). Since BASCs have been characterized to be CD31- 
CD45- Sca1+ (Tyler J et al., 2005); in the present study BASCs were isolated by employing 
fluorescent activated cell sorting (FACS) detailed in the methods section. The population of 
BASCs isolated was observed to be about 80% pure based on dual positive immunofluorescence 
staining for CC10 and SP-C (CC10+ SP-C+) on the sorted population. At 3 months post-
cigarette smoke exposure, a 3.5-fold increase (p≤0.05) in CD31- CD45- Sca1+ BASCs was 
observed when compared to their room-air exposed counterparts (Figure 7B). Moreover, after 6 
months exposure to chronic cigarette smoke the percentage of CD31- CD45- Sca1+ BASCs was 
observed to increase by 5-fold in contrast to their controls (Figure 7B). These results show a 
significant expansion of the BASC cell population in the cigarette smoke exposure model of 
emphysema (Figure 7B), similar to the results from the PPE injury model (Figure 7A). 
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Figure 7: Expansion of BASC in the terminal BADJ on emphysema-associated injury 
Panel (A):  Naïve C57BL/6J mice were treated IT with 1.5 units of PPE/PBS. Lung sections from the mice were 
dual stained for CC10 and SP-C. The number of dual positive (CC10+ SP-C+) cells were quantified over the course 
of 21 days and averaged to the number of BADJs counted per specimen. Panel (B): Whole lung cell isolates from 8-
10 mice (C57BL/6J) exposed to chronic cigarette smoke for 3 months, 6 months and their room-air exposed controls 
were stained for CD31, CD45 and Sca-1. Fluorescence activated cell sorting (FACS) for the CD31- CD45- Sca-1+ 
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population sorted the BASC population specifically. The percentage of CD31- CD45- Sca-1+ cells sorted was plotted 
as a function of month’s post-cigarette smoke exposure. 
3.3.3 Migration of distal bronchial progenitor cells from the terminal bronchiole in the 
context of alveolar injury 
Alveolar injury has been shown to stimulate the proliferation, migration and differentiation of 
AT-II cells into AT-I cells on alveolar epithelial cell loss. Due to the lack of intracellular markers 
apart from CC10 that define Clara cells and SP-C that define AT-II cells, we were limited in our 
capacity to specifically follow the contribution of BASCs in the alveolar compartment and so 
chose to monitor the CC10 expressing distal bronchial progenitor cells (these include the BASCs 
as well) in the distal bronchi from this point on. To investigate the contribution of distal 
bronchial progenitor cells towards alveolar repair, transgenic CC10-Cre; ROSA-LacZ mice were 
exposed to PPE administered through the intra-tracheal route while their controls received an 
equivalent volume of PBS. The mice were sacrificed on 3, 5, 7, 10, 14 and 21 days post-exposure 
to PPE or PBS, their lungs processed for paraffin embedding and sectioning. Quantification of β-
Gal+ cells just past the bronchoalveolar duct junction (BADJ), showed a significant and 
progressive increase in the number of cells that stained positive with X-Gal in the PPE exposed 
group in contrast to the PBS treated controls (Figure 8A). The number of β-Gal+ lineage tagged 
cells just past the bronchoalveolar duct junction (BADJ) increased from 2.4- to 3-fold between 
day 10 to day 21 post-PPE exposure compared to their respective PBS exposed controls (Figure 
8A). Representative bright field images of lung sections shown in Figure 8B indicated a visual 
increase in the numbers of β-Gal+ cells emanating from the BADJ in the lung sections from mice 
that received PPE at 21 days post-exposure when compared to their PBS controls.  These 
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observations when taken together, show a significant expansion in this progenitor cell population 
that proceed to migrate in significant numbers from their niche at the terminal bronchoalveolar 
duct junction into the adjacent injured alveolar parenchyma, as evidenced in the PPE injury 
model. 
 
Figure 8: Migration of distal bronchial progenitor cells from the terminal bronchi in response to alveolar 
injury 
CC10-Cre; ROSA-LacZ transgenic mice were exposed to 1.5 units of PPE (IT) and the control group received PBS. 
The mice were sacrificed at the various time points, their lungs inflated and stained in X-Gal solution. (A) 
Quantification of β-Gal+ cells just past the BADJ into the alveoli, indicating a progressive and significant increase in 
the numbers of β-Gal+ cells emanating from the BADJ in the PPE exposed mice over the course of 21 days as 
compared to their PBS controls. (B) Representative bright field images (at 60X magnification) of X-Gal stained 
lungs from mice 21 days post-PBS exposure (on left) and 21 days post-PPE exposure (on right) indicating blue (β-
Gal+ lineage tagged) cells emanating from the distal bronchi of the lung. 
3.3.4 Distal bronchial progenitor cells enter the alveolar space in response to emphysema 
associated alveolar injury 
Following movement from the distal airway into the local alveolar junction, we also investigated 
migration throughout the alveolar space following PPE or cigarette smoke associated alveolar 
injury. We assessed this based on preliminary results, which indicated an increased migration of 
 71 
these cells from their niche on PPE associated alveolar injury. Transgenic CC10-Cre; Rosa-LacZ 
mice were sacrificed at various time points post-PPE exposure and their lungs processed as 
elucidated earlier. The number of blue (β-Gal+ lineage tagged) cells were quantified from bright 
field images of X-Gal stained lung sections for each time point shown in Figure 9A. 
Morphometry was performed on the lung sections to determine their mean chord length, which 
was used to calculate their mean alveolar tissue density. The y-axis in Figure 9A shows the 
average numbers of β-Gal+ lineage tagged cells quantified per specimen that were normalized to 
their alveolar tissue density at each time-point post-exposure to PPE or PBS. The data indicated a 
significant increase in the numbers of blue-tagged cells in the alveolar space of mice that 
received PPE when compared to their PBS exposed controls. Additionally, a progressive increase 
in the migration of the β-Gal+ lineage tagged cells was observed into the injured alveolar 
compartment of the lung over the span of 21 days-post PPE exposure when compared to their 
PBS exposed counter-parts (Figure 9A). The bright field lung images shown in Figure 9B, reveal 
that more blue-tagged cells (β-Gal+) were present in the alveolar space at day 21 post-PPE 
exposure (right panel) when compared to their controls (left panel). 
 To elucidate if cigarette smoke induced injury had a similar effect on the migration of β-
Gal+ lineage tagged cells into the alveolar space as seen with the PPE- injury model, 8-12 week 
old transgenic female mice were exposed to chronic cigarette smoke and sacrificed after 3 and 6 
months smoke exposure while their controls were exposed to room-air. Quantification of the 
number of blue cells (β-Gal+ lineage tagged) in the alveolar space (Figure 9C) demonstrated a 2-
fold increase in lineage tagged cells on 3 months exposure to cigarette smoke when compared to 
their room-air exposed controls. By 6 months of chronic smoke exposure, the number of blue 
cells (β-Gal+ lineage tagged) in the alveolar space was 3 times more in contrast to their room-air 
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exposed controls which were mostly unaltered over the course of 6 months (Figure 9C). This 
increase in numbers of blue cells (β-Gal+ lineage tagged) in the 6 month smoke exposed mice 
(right panel) in contrast to their room air-exposed controls (left panel) is reflected by 
representative bright field images of lung sections stained for X-Gal, as shown in Figure 9D. 
These results considered together indicate a critical contribution of the β-Gal+ lineage tagged 
terminal bronchial progenitor cells towards migrating into the injured alveolar compartment of 
the lung in response to PPE or cigarette smoke associated injury in a potential attempt to repair. 
 
 
Figure 9: Migration of Distal bronchial progenitor cells from the BADJ into the injured alveolar 
compartment of the lung 
Transgenic (CC10-Cre; ROSA-lacZ) mice were exposed to PPE/PBS over the course of 21 days (A&B) or exposed 
to chronic cigarette smoke/room-air for 3 and 6 months (C&D) before being sacrificed. The lungs from these mice 
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were inflated, stained with X-Gal and processed for sectioning as detailed in the methods. (A) β-Gal+ lineage tagged 
cells that enter the alveolar space were quantified and normalized to the alveolar tissue density. PPE exposed mice 
displayed a significant increase in the numbers of β-Gal+ cells in the alveolar space, which showed a linear 
progression as a function of days post-exposure in contrast to the PBS exposed controls. (B) Representative bright 
field (BF) images at 40x magnification of 21days post- PBS exposed (on left) and post-PPE exposed (on right) X-
gal stained lung sections indicating the presence of blue (β-Gal+ lineage tagged) cells in the alveolar space. (C) 
Cigarette smoke exposure leads to ~ 2 fold increase in β-Gal+ cells at 3 months post-exposure and by 6 months this 
progresses to ~3 fold increase in lineage tagged cells entering the alveolar space when compared to their respective 
controls. (D) Visualization of representative BF image of a 6-month room-air exposed controls indicating relatively 
fewer blue (β-Gal+ lineage tagged) cells as compared to the 6 month cigarette smoke exposed (on right) lung 
section. 
3.3.5 Lineage tagged distal bronchial progenitor cells give rise to alveolar type-II and 
alveolar type-I epithelial cells 
The increased migration of lineage tagged terminal bronchial progenitor cells into the injured 
alveolar compartment of the lung leads to the question as to whether they differentiate into the 
local alveolar epithelial cell population or not. To investigate this, X-Gal stained lung sections 
obtained from transgenic CC10-Cre; Rosa-LacZ mice exposed to PPE or PBS through intra-
tracheal (IT) instillation were examined. These lung sections demonstrated bright blue staining in 
their β-gal expressing parent (in the terminal bronchi) and daughter cells (in the alveolar space) 
irrespective of their CC10-expression status. As shown in Figure 10, bright blue staining was 
observed not only in the CC10-expressing airway epithelium (Figure 10, panels A and B) but 
also in the alveolar type-II (AT-II) epithelial cells that are present in the alveolar parenchyma in 
the PPE exposed group (Figure 10, panels B and D). Alveolar type-I (AT-I) epithelial cells 
however are thinner and have elongated cell bodies leading to poor visualization of the stain, 
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hence a blue speckling on staining with X-gal is observed. At 21 days post-PPE exposure the 
blue speckling in the AT-I epithelial cells was observed to be more predominant (indicated by 
arrows in Figure 10, panels B and D) when compared to their PBS exposed controls (Figure 10, 
panels A and C). 
 
Figure 10: β-Gal+ lineage tagged cells arising from the terminal bronchi give rise to AT-I and AT-II epithelial 
cells post-PPE injury 
Representative bright field images at 60X magnification from 21 day PBS treated mice stained with X-Gal show 
bright blue staining in their airways, some staining on the AT-II epithelial cells and no significant staining in their 
AT-I epithelial cells (A & C). The 21-day PPE exposed mouse lungs in contrary showed bright blue staining on 
their AT-II epithelial cells as well as blue speckling in their AT-I cells (indicated by the arrows) as shown in panels 
(B & D) on the right. 
To validate if the lineage tagged β-Gal+ cells that enter the alveolar compartment from 
the BADJ truly differentiate into AT-II epithelial cells, lung sections were dual stained for SP-C 
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(AT-II cell specific marker) and CC10 (a Clara cell specific marker) to monitor the β-Gal+ 
tagged cells in the alveolar parenchyma. Comparing the representative bright field images 
(Figure 11B) to the dual IF stained fluorescence images (Figure 11D) of lung sections from PPE 
treated mice at 21 days post-exposure, a large number of blue (β-Gal+ lineage tagged) cells in 
the alveoli were found to stain positive for SP-C (indicated by arrows in Figures 11B and 11D). 
Additionally, similar expression of SP-C in the blue staining cells was observed in the alveoli of 
the PBS controls although fewer in number than in the PPE treated mice (Figures 11A and 11C). 
The loss of CC10 expression and the subsequent gain of SP-C expression by the lineage tagged 
(β-Gal+) cells originating from the BADJ confirms that the lineage tagged (β-Gal+) cells which 
originate from the BADJ truly differentiate into AT-II epithelial cell in the context of PPE 
associated alveolar injury. 
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Figure 11: SP-C expressing β-Gal+ lineage tagged cells visualized around the BADJ on PPE exposure 
X-Gal stained lungs from 21-day PPE exposed and PBS exposed mice were dual stained using immunofluorescence 
for CC10 (Clara specific) and SP-C (AT-II specific). Top panels indicate representative bright field images of a PBS 
exposed mouse lung (A) and a PPE exposed mouse lung (B), 21 days post-exposure. Bottom panels show 
corresponding fields imaged by fluorescence microscopy, indicating SP-C in green (AT-II specific marker) and 
CC10 in red (Clara cell specific). The β-Gal+ linear tagged cells staining blue in the alveolar compartment 
additionally stain positive for SP-C (indicated by arrows) in both PPE exposed (D) mice and their PBS exposed 
controls (C) 21 days post-IT exposure. 
 
Finally, we examined lung sections from transgenic (CC10-Cre; Rosa-LacZ) mice that 
had been exposed to chronic cigarette smoke/ room air for 6 months to trace the β-Gal+ lineage 
tagged cells from the distal airway into the alveolar space, to confirm our observations in the 
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PPE injury model. Representative bright field images from 6-month smoke exposed mice in 
Figure 12, panels B and D; indicated bright blue staining in the cuboidal AT-II epithelial cells as 
well as the wispy AT-I epithelial cells. The room-air exposed control mice did not show 
significant blue staining on the AT-I or AT-II epithelial cells around the BADJ (Figure 12A) or 
lining the alveolar space (Figure 12C). Together these observations, confirmed the true 
differentiation of β-Gal+ lineage tagged cells into AT-I and AT-II epithelial cells that repopulate 
the damaged alveoli. 
 
Figure 12: β-Gal+ lineage tagged cells arising from the terminal bronchi give rise to AT-I and AT-II epithelial 
cells post-cigarette smoke induced injury 
Top panels (A & B) show representative bright field images at the BADJ of X-Gal stained lung tissue and the 
bottom panels (C & D) show images from the alveolar parenchyma at 60X magnification. The CC10-Cre; Rosa-
LacZ transgenic mice were exposed to chronic cigarette smoke (B & D) over a period of 6 months and their controls 
to room-air (A & C). The black arrows (→) point at blue speckling observed in the AT-I epithelial cells (β-Gal+ 
lineage tagged) predominantly in the 6 month cigarette smoke exposed mouse lung sections (B & D). Bright blue 
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staining was observed in the AT-II cells at the BADJ both in the chronic smoke exposed (B) as well as the shams 
(A). 
3.3.6 Lineage tagged cells emanate from the BADJ and repopulate the alveoli in a 
constitutive CC10-iCre; Rosa-LacZ knock-in mouse line in the context of PPE associated 
injury 
The transgenic (CC10-cre; Rosa-LacZ) mouse line developed in-house when tested for 
specificity and exclusivity of Cre expression in CC10 expressing cells showed no leakiness of 
Cre expression by immuno histochemistry. Nevertheless to rule out the possibility that the 
transgenic Rat CC10 promoter may have leaky expression below the threshold of detection of the 
tests performed; we used a knock-in CC10-iCre; Rosa –LacZ mouse line to validate our findings. 
To investigate if the distal bronchial progenitor cells present at the BADJ expressing lacZ 
emanated into the injured alveolar space, 8-12 week old female CC10-iCre; Rosa-LacZ knock-in 
mice were exposed to intra-tracheal (IT) instillation of PPE or PBS for 21 days. The mice were 
sacrificed at the end of 21 days, their lungs inflated and stained for X-Gal. Quantification of the 
numbers of β-Gal+ cells past the BADJ indicated a significant increase (3-fold) in the PPE-
exposed mice when compared to their PBS exposed controls (Figure 13A). Visualization of 
representative bright field images (Figure 13B) of lung sections from the PPE-exposed mice 
(right panel) indicated more blue (β-Gal+ lineage tagged) cells adjacent to the terminal bronchi 
in contrast to their controls (left panel). These observations from the knock-in mouse line 
corroborated the initial findings described earlier in the transgenic mouse line and emphasized 
the critical contribution of the distal bronchial progenitor cells (initially CC10 expressing) in 
repopulating the injured alveolar compartment. 
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Figure 13: Migration of β-Gal+ lineage tagged cells from the BADJ into the damaged alveoli in the knock-in 
mouse model 
Knock-in CC10-iCre; Rosa-LacZ mice were instilled IT with 1.5 units of PPE, the mice sacrificed at 21 days since 
exposure, their lungs inflated and stained with X-Gal. (A) Quantification of numbers of blue (β-Gal+ lineage tagged) 
cells near the BADJ indicated significantly increased lineage tagged cells emanating from the BADJ at 21 days post-
PPE exposure as compared to their controls. (B) Representative bright field images of lung sections from mice 
exposed to PBS (on left) and PPE (on right) at 21 days post-exposure indicating lineage tagged cells near the BADJ 
at 40X magnification 
 
In addition, dual immunofluorescence staining on lung sections from these knock-in mice 
were stained for CC10 and SP-C, this confirmed that the β-Gal+ lineage tagged cells emanating 
from the BADJ were truly giving rise to SP-C expressing AT-II cells in the alveolar epithelium. 
Comparative analysis of bright field images of X-Gal stained lung sections along with their dual 
immunofluorescence stained counterparts clearly showed that a number of blue (β-Gal+ lineage 
tagged) cells that had emanated into the alveolar space actively expressed SP-C (AT-II cell 
specific marker) as indicated by the arrows in Figure 14A and 14B. These findings in the knock-
in mouse line when taken together with the increased recruitment of distal bronchial progenitor 
cells (DBPCs) into the damaged alveoli, confirm that the DBPCs emanating from the distal 
terminal bronchi lose their CC10- expression status and begin actively expressing SP-C as they 
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repopulate the alveolar parenchyma of the lung. Validation of our experimental observations in 
the transgenic mouse line using the knock-in mouse line highlighted the critical role of these 
DBPCs in mediating alveolar repopulation especially under alveolar-associated damage. 
 
Figure 14: β-Gal+ lineage tagged cells emanating from the BADJ into the alveolar space express SP-C 
Knock-in CC10-iCre; ROSA-LacZ mouse lungs stained for X-Gal and dual immunofluorescence stained. Panel A: 
representative bright field image at 40X magnification of the X-Gal stained lung. Panel B shows the same field 
imaged by fluorescence microscopy, indicating SP-C in green (AT-II specific marker), CC10 in red (Clara cell 
specific) and DAPI in blue. Arrows indicate β-Gal+ lineage tagged cells that have taken on active SP-C expression 
(AT-II epithelial cell specific) while no longer expressing CC10. 
3.4 DBPC- DISCUSSION 
Understanding the events that lead to lung tissue damage/destruction coupled with the activation 
of adult stem/progenitor cell populations facilitating lung repair and maintenance is critical to the 
study of regenerative medicine. Several adult lung progenitor cell populations have been 
implicated in repairing the airway or the alveolar compartment of the lung using a variety of 
chemical injury models, however the contribution of a single adult lung progenitor cell 
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population in both compartments of the lung has remained controversial. A number of lung 
pathologies have been characterized by the loss or modification of specific cell subsets in 
response to insult, including mutations in certain cell populations leading to cancers and 
oxidative/cellular stress leading to senescence, apoptosis or necrosis. Specifically in emphysema, 
a common manifestation of COPD, we observe a significant loss of the alveolar units within the 
lung parenchyma. In the present study, our data points towards compelling evidence highlighting 
the contribution of previously described (Giangreco, Reynolds et al. 2002, Kim, Jackson et al. 
2005) distal bronchial progenitor cell populations (BASC and variant Clara cells) nestled in the 
terminal bronchoalveolar duct junction (BADJ) towards alveolar repair in the context of 
emphysema associated injury.  
Bronchoalveolar stem cells (BASC), initially described to be resistant to airway (naphthalene) 
and alveolar (bleomycin) injury, were shown to proliferate in presence of oncogenic K-Ras. In 
vitro studies have indicated their capacity to differentiate into both CC10 expressing Clara cells 
as well as SP-C expressing alveolar type-II epithelial cells (Kim, Jackson et al. 2005). Although 
the BASCs were initially characterized to express cell surface markers: stem cell antigen- 1 (Sca-
1) and cluster of differentiation 34 (CD34) and lack expression of CD31 (endothelial cell 
marker) and CD45 (a marker of hematopoietic cells); recent studies have questioned the 
exclusivity of these markers on these putative stem cells (McQualter, Brouard et al. 2009, 
Hittinger, Czyz et al. 2013). Aware of this limitation we decided to strictly monitor the 
contribution of CC10 expressing distal bronchial progenitor cells (DBPCs) using a transgenic 
CC10-Cre; Rosa-LacZ mouse strain as a tool for lineage tracing. Using this system, we studied 
the expansion and migration of these cells from the BADJ into the surrounding alveolar space 
under porcine pancreatic elastase (PPE) induced alveolar injury. The significantly elevated 
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numbers of β-gal+ lineage tagged progenitor cells at the BADJ and their subsequent migration 
into the (PPE mediated) injured alveolar parenchyma (Figure 8, Figure 9A and 9B) were 
corroborated in the GOLD standard 6-month cigarette smoke model (Figure 9C and 9D), which 
indicated a similar involvement of these progenitor cells in repopulating the damaged alveolar 
compartment of the lung.  
Dual immunofluorescence staining for surfactant protein-C (SP-C), an alveolar type-II epithelial 
cell specific marker in addition to Clara cell specific secretory protein-10 (CC10) on X-Gal 
stained lung sections, enabled for the quantification of β–Gal+ cells that had migrated into the 
alveolar compartment and subsequently differentiated into alveolar type-II epithelial (AT-II) 
cells. Bright field imaging of X-gal stained transgenic mouse lung sections displayed bright blue 
staining on the AT-II cells; while the wispy and thin alveolar type-I epithelial (AT-I) cells 
displayed blue speckling in their stretched out cytoplasm (Figure 10, 11 and 12). Using a Rosa-
eYFP reporter mouse crossed with the transgenic RatCC10-Cre mouse, we traced these bronchial 
progenitor cells that had given rise to both SP-C expressing AT-II cells and aquaporin-5 (AQP-5) 
expressing AT-I cells by dual immunofluorescence staining for enhanced yellow fluorescent 
protein (eYFP) (not shown). Our findings confirm the direct contribution of β–Gal positive 
lineage tagged cells (distal bronchial progenitor cell) that arose from the terminal bronchial duct 
junction and gave rise to both alveolar type-I and type-II epithelial cells in the injured alveolar 
parenchyma. 
Contrary to findings from other studies that suggest that these CC10 positive lineage tagged 
bronchial progenitor cells do not play a role in alveolar repair (EL Rawlins et. al, 2009), results 
obtained from our transgenic mouse line used to lineage trace the CC10+ progenitor cells 
migrating from their niche in the terminal bronchiole showed a significant repopulation of the 
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injured alveolar compartment. The reasoning behind these differing observations could stem 
from the fact that different injury models (hyperoxia versus PPE) may have very different 
cellular and structural outcomes in vivo. Further, the tamoxifen inducible (dose-dependent) Cre 
expression system has its own limitations (dose dependency) when used to lineage trace cells 
from their niche. In a subsequent independent study, the CC10-CreERTM mouse line developed 
by Hogan’s group was bred with an ACTB-mT-EGFP transgenic mouse line to develop a lineage 
tracing system that would enable the authors to look at the contribution of the CC10-expressing 
population stemming from the airways towards alveolar repair (Zheng, Limmon et al. 2012). 
Their results indicated similar regenerative potential of CC10 (also known as 
secretoglobulin1a1- scgb1a1) expressing distal airway-derived cells towards repopulating the 
damaged alveolar compartment under bleomycin and influenza associate injury (Zheng, Limmon 
et al. 2012). These observations support and further strengthen the results obtained in the present 
study utilizing the transgenic mouse model (RatCC10-Cre; Rosa26-LacZ). 
 The specificity of Cre expression on RatCC10 expressing cells lining the airways was 
investigated by immunofluorescence (IF) staining on lung sections from the transgenic mice 
(RatCC10-Cre; Rosa-LacZ) exposed to PPE over the course of 21 days. Visualization post-IF 
staining by fluorescence microscopy revealed that Cre recombinase expression was limited to 
RatCC10 expressing cells lining the airways of these transgenic mice (Appendix A, Figure 15 
and 16). To overrule non-specific Cre expression or expression of Cre below our threshold for 
detection in the transgenic mouse line, we obtained a CC10-iCre knock-in mouse line that 
expressed an improved version of Cre recombinase under the endogenous mouse CC10 promoter 
(Li, Cho et al. 2008). This knock-in mouse line initially generated by DeMayo’s group at Baylor 
college of medicine was bred with our Rosa26-LacZ reporter mouse line to generate a CC10-
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iCre knock-in mouse strain (CC10-iCre; Rosa-LacZ) that expressed LacZ in all its endogenous 
CC10-expressing cells. Exposure of this knock-in mouse line to PPE over 21 days confirmed the 
migration of the CC10 expressing β-Gal+ lineage tagged cells into the damaged alveolar 
compartment (Figure 13). Additionally, we did observe β-Gal+ lineage tagged cells in the knock-
in mouse line that enter the alveolar compartment actively expressing SP-C on loosing their 
CC10 expression status, thereby differentiating into AT-II epithelial cells (Figure 14).  
Alveolar type-II epithelial cells have long been implicated as a progenitor cell population for the 
more fragile alveolar type-I epithelial population (Evans, Cabral et al. 1975, Aso, Yoneda et al. 
1976). However, whether all AT-II cells are uniformly able to regenerate and replenish AT-I 
cells is unclear. Under PPE and cigarette smoke related injury; loss of AT-I cells can lead to the 
proliferation and differentiation of AT-II cells into AT-I cells. Further as indicated in our 
transgenic and knock-in mouse models, we observe that the CC10 expressing terminal bronchial 
epithelial progenitor cells differentiated into AT-II cells and perhaps AT-I cells even (Figures 
10,11,12 and 14). In staining for SP-C and Ki67 (a marker of proliferation) not only did we 
observe an increase in the SP-C expressing AT-II cell population post-injury but that these cells 
were actively proliferating (not shown). These findings suggest a multi-cellular approach 
towards repair of the damaged alveolus, although the specific sequence and extent of 
contributions are undetermined. 
Our study defines a role for CC10+ distal bronchial progenitor cells towards repairing and re-
populating the injured alveoli under emphysema-associated injury. By understanding the stimuli 
that potentiate the activation of these progenitor cells causing them to proliferate, migrate into 
the injured alveolar compartment and differentiate into local alveolar epithelium, we can aim at 
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recreating the same environment and triggers to elicit endogenous repair. Thus hope to treat this 
devastating disease. 
3.5 DBPC- FUTURE DIRECTIONS 
The results of this study demonstrate that distal bronchial progenitor cells in the terminal 
bronchiole are capable of re-populating damaged alveoli by giving rise to alveolar type-II and 
type-I epithelial cells. The nature of molecular cues that lead to the activation of these progenitor 
cells perhaps during early lung development may lead us to better understand how we may 
recapitulate the activation of these cells to repair in the context of injury. Fibroblast growth 
factor-10 (FGF10) and FGFR2b (fibroblast growth factor receptor 2 (III) b) null mice have been 
shown to have normal larynx and tracheal development, however they lacked distal bronchi. 
Several other studies as well have highlighted the importance of FGF10-FGFR2b signaling in 
amplifying peripheral progenitors in early lung development [106, 258, 259]. Inhibition of 
epidermal growth factor (EGF) expression during early mouse lung development showed a 75% 
decrease in branching lung morphogenesis [260]. Deficiency in Smad-3, a main intracellular 
mediator of transforming growth factor-β (TGF-β) receptor signaling caused early onset of 
emphysema due to disrupted organization of matrix and increased MMP activity [259]. Most of 
the studies outlined above point towards the involvement of growth factors and intracellular 
mediators in alveolar morphogenesis. In the future we would need to study the roles of these 
factors on the distal bronchial progenitor cell population and how they may potentiate a micro-
environment suitable for repair in the context of cigarette smoke induced alveolar injury. One 
may argue that these distal bronchial progenitor cells being an adult progenitor cell population 
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with limited differentiation potential may find limited application while studying the role of 
developmental cues in the context of injury, however that said recent studies highlight epithelial 
adaptability and their capacity to reversibly express mesenchymal features to aid in tissue 
remodeling [261]. Hence the lung microenvironment and cross-talk between neighboring cells 
may largely dictate the activation of these progenitor cell populations in their niche to self-
renew, migrate and differentiate into terminally differentiated epithelial cell populations 
especially in the context of injury. 
In order to repair; progenitor cells need to be able to proliferate, migrate and differentiate 
into the local epithelial cell population. Matrix metalloproteinases (MMPs) have been implicated 
in regulating growth factor availability, remodeling cell-cell and cell-matrix contacts and 
promoting overall cell-survival [262]. Several MMPs have been shown to cause EGF release 
from the underlying basement membrane [263, 264]. MMP-7 or Matrilysin has been shown to 
contribute to airway epithelial cell repair [265]. MMP-9 null mutant mice were shown to have 
impaired alveolar bronchiolarization on bleomycin-induced injury when compared to their wild-
type counter-parts [266]. Therefore our next steps would involve studying the expression of key 
MMPs and their involvement in DBPC migration in the context of cigarette smoke induced 
alveolar injury. 
Identification of cell surface markers that specifically characterize progenitor cell 
populations in the lung coupled with the advancement of techniques that can enable us to 
specifically study progenitor population subsets will lead to a better understanding of relative 
contributions of these cells under homeostasis and in the context of injury. Recent approaches to 
characterizing cell surface markers involve isolating proteoglycans in the cell membrane using 
an enzyme-free cell dissociation solution and purified by affinity chromatography, known as cell 
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surface capture (CSC) technology. The isolated peptides (affinity purified) are further analyzed 
by mass spectrometry and the resultant spectra are analyzed using bioinformatic and hierarchical 
clustering databases to identify new cell surface proteins [267-269]. By systematically isolating 
and identifying the cell surface proteins on CC10 expressing DBPCs, CC10+ terminally 
differentiated Clara cells, CC10+ SP-C+ BASCs, SP-C+ alveolar type-II progenitor cells and 
terminally differentiated AT-II cells, we can hope to better dissect their independent roles in 
alveolar repopulation in the context of injury. 
Aside from assessing the mechanistic roles of these progenitor cells, we do observe better 
repair responses in female mice in comparison to their male counterparts. Gender based 
differences in reparative responses and the extent of injury have been discussed in different 
injury models [270, 271]. Yet we do not completely understand how gender may impact an 
organ’s ability to repair or sustain damage. Further, mouse models have their own limitations in 
that they do not entirely reflect the complexity seen in human disease. Environmental exposure, 
genetic susceptibility, variable response to treatment, variation in injury observed and general 
lifestyle habits have been shown to impact the extent of human disease. Hence finding an 
analogous human progenitor cell population sharing the same capacity to repair and regenerate 
the alveolus as investigated in a mouse model is a goal. Realization of which will enable us to 
translate these observations into potential treatments in the clinic. 
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APPENDIX A 
SELECTIVITY AND SPECIFICITY OF RAT-CC10 PROMOTER EXPRESSION IN 
CC10-CRE; ROSA-LACZ TRANSGENIC MICE 
In order to validate the specificity of Cre recombinase expression and exclude the possibility of a 
random insertion of the RatCC10 promoter - CRE construct in the mouse genome, we performed 
immunofluorescence staining for RatCC10 and Cre recombinase on transgenic mice that were 
exposed to PPE (intra-tracheal) and compared them to their controls that received PBS. The 
immunofluorescence staining for Cre and visualization by fluorescence microscopy confirms that 
Cre is expressed specifically in the airways and not in the alveolar parenchyma, both in the 
presence and absence of injury (Figure 15). Further staining for Rat CC10 confirms its 
expression to be limited to the airways in the lungs of the transgenic mice in the presence of PPE 
induced injury (Figure 16). These findings confirm that the Rat CC10 promoter is not leaky in its 
expression and that its subsequent expression of Cre recombinase is limited to epithelial cells 
lining the airways in the lungs of the transgenic mice. 
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Figure 15: Cre expression limited to the airways and not found in the lung parenchyma. 
Transgenic CC10-Cre; ROSA-LacZ mouse lungs exposed to PPE (panels on right) were stained for Cre expression 
over the course of 21 days and compared to their PBS controls (panels on left). The nuclear stain (DAPI) used stains 
blue and Cre stains in red. 
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Figure 16: Rat CC10 promoter expression is airway specific even on injury. 
Transgenic CC10-Cre; ROSA-LacZ mouse lungs exposed to PPE (panels on right) were stained for Rat CC10 
expression over the course of 21 days and compared to their X-Gal stained bright field images (panels on left). In the 
immunofluorescence staining, blue indicates the nuclear staining (DAPI), red indicates the Rat CC10 staining and 
green indicates SP-C staining. 
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APPENDIX B 
RAGE EXPRESSION ON CHRONIC CIGARETTE SMOKE EXPOSURE 
B.1 BACKGROUND 
The expression of RAGE on lung tissue from subjects with COPD was significant elevated in the 
alveolar walls and not in their airways [158]. In vitro studies performed exposing a rat alveolar 
type-I epithelial cell line (R3/1), a macrophage cell line (RAW264.7) and a human lung 
adenocarcinoma cell line (A549) to cigarette smoke extract demonstrated an elevation in the 
expression of RAGE and its ligands [161]. These studies and others linking RAGE expression to 
the severity of disease led to the investigation of the expression of RAGE on wildtype mice 
(C57BL/6J background) that had been exposed to cigarette smoke over the course of 6 months.  
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B.2 MATERIALS AND METHODS 
B.2.1 Mice 
8-12 week old C57BL/6J female mice were used. N=8-10 mice per group per experimental 
condition. 
B.2.2 Cigarette smoke exposure 
C57BL/6J female mice were exposed to 4 unfiltered cigarettes (University of Kentucky) a day, 5 
days a week for 6 months using a smoking apparatus [8] 
B.2.3 RAGE immunofluorescence staining 
Lung sections were de-waxed and rehydrated. Following antigen retrieval with 1mg/ml pepsin, 
slides were blocked in 2% BSA/PBST solution for 1hr room temperature. The sections were 
incubated with rabbit α-mouse RAGE antibody at 1:1000 dilution in 2%BSA/PBST [272]; at 4˚C 
overnight. After washing the slides in PBS (3x), Donkey αRabbit Alexa fluoro 594 antibody 
(Invitrogen) in 0.5% BSA/PBST was added and incubated for 1hr at room temperature. The 
slides were washed, nuclei stained with DAPI and coverslips were finally applied. 
B.2.4 Tissue homogenization, protein quantification and immunoblotting 
Whole lungs isolated from C57BL/6J mice exposed to 6 months of cigarette smoke and their 
respective controls were homogenized in isotonic buffer with CHAPS detergent (50 mM Tris-
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HCl, pH 7.4, 150 mM NaCl, 10 mM CHAPS) with protease inhibitors (100 µM 3,4-
dichloroisocoumarin (DCI), 10 µM trans-epoxysuccinyl-L-leucylamido- (4-guanidino) butane 
(E-64), 2 mM o-phenanthroline monohydrate- all from Sigma) and sonicated briefly [273]. The 
total lung homogenates were quantitated using the BCA standard protein assay kit  (Thermo 
Fisher). 10µgs of protein per sample was separated by SDS-PAGE and transferred to PVDF 
membranes as described previously [273]. The membranes were blocked overnight in 5% nonfat 
dry milk/PBST at 4⁰C. The membranes were then incubated with 1:5000 Rabbit anti-mouse 
RAGE primary and 1:10,000 anti-rabbit HRP secondary antibodies for 1 hr at room temperature. 
The membranes were washed with PBST (3x for 10 min) after each incubation. The reactive 
bands were visualized using the chemiluminescence method (SuperSignal West Pico, Pierce). 
The same membranes were probed with β-actin (1:1,000; Cell Signaling) as loading controls. 
B.3 RESULTS 
B.3.1 Immunofluorescence (IF) staining indicates no visible difference in RAGE 
expression 
To test if there was any alteration in RAGE expression in mouse lung tissue on chronic cigarette 
smoke exposure, we stained lung sections from wildtype (C57BL/6J) mice that had been exposed 
to chronic cigarette smoke and compared them to their room air exposed controls. The antibody 
used in staining for RAGE expression showed specific binding to RAGE evident from the 
absence of staining in a RAGE deficient control (Figure 17, panel a). However, IF staining of 
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wildtype mouse lung sections indicated no visual difference in the intensity of staining 
irrespective of their exposure to cigarette smoke. 
 
Figure 17: Immunofluorescence for RAGE shows no alteration of expression on cigarette smoke exposure 
Representative images of IF staining performed on paraffin sections indicating RAGE expression (in RED) and 
DAPI (nuclear stain in BLUE). Representative images obtained at 40X magnification (a) naïve RAGE-/- (b) 
C57BL/6J (non-smoke) room air exposed mouse lung (c) C57BL/6J 6 month cigarette smoke-exposed mouse lung 
B.3.2 Chronic cigarette smoke exposure led to the loss of X-RAGE 
To quantitatively assay the expression of RAGE protein and its isoforms in mice, we analyzed 
total lung homogenates isolated from wildtype mice exposed to 6 months of cigarette smoke and 
compared them with their room air exposed controls. Western blotting for RAGE indicated to us 
the presence of three bands with molecular sizes 57.4 kDa, 52.6 kDa and 45.1 kDa 
corresponding to X-RAGE, membrane RAGE  (mRAGE) and soluble RAGE (sRAGE) 
respectively as described previously [274]. Immunoblotting made apparent the loss of the X-
RAGE isoform on chronic cigarette smoke exposure (Figure 18, top panel). Further 
quantification of band densities made clear that there was a significant loss in the X-RAGE 
isoform on chronic cigarette smoke exposure in the wildtype mice as compared to their room air 
exposed controls (Figure 18, bottom panel). However mRAGE and sRAGE levels remained 
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largely unaltered in the group that received chronic cigarette smoke exposure when compared to 
their controls (Figure 18). 
 
 
 
Figure 18: Quantification of RAGE isoforms indicates no alteration in membrane RAGE expression on 
chronic smoke exposure. 
Immunobloting for RAGE and β-actin (loading control) on whole lung homogenates from C57BL/6J mice exposed 
to 6months cigarette smoke and their non-smoke controls (Top panel). Quantification of RAGE signal intensity 
normalized to β-actin using ImageJ for each RAGE isoform (Bottom panel) 
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B.4 DISCUSSION 
X-RAGE, a membrane bound isoform of RAGE is exclusively found in mouse lung tissue. 
Affinity column purified X-RAGE was analyzed by mass spectrometry and yielded identical 
peptide fragments as that obtained on analysis of mRAGE [274]. Hence there is no clear 
indication as to what could contribute to the difference in molecular sizes, however de-
glycosylation studies of RAGE point towards the possibility of an additional N-linked glycan of 
approximately 1.7kda in the case of X-RAGE [274]. X-RAGE was significantly reduced in the 
chronic smoke exposed group of mice when compared to their air-exposed controls. We are 
unsure of what the physiological indication of this could be in the context of cigarette smoke 
induced emphysema, given the nature of this isoform. However, we do not observe any 
significant alteration in mRAGE or sRAGE expression and this correlates with the lack of any 
visual alteration in immunofluorescence intensity of RAGE staining (Figure 17 and 18). These 
observations may not mirror observations reported in COPD subjects and may very well be 
attributed to the differences in model systems. Nevertheless, when we exposed RAGE null 
mutants to chronic cigarette smoke over a period of 6 months, we do observe that these mice 
display a significant protection in comparison to their wildtype counterparts (Figure 1E). These 
observations when considered together suggest a role for RAGE in mediating the progression of 
emphysema; at the same time they may also indicate the possible activation of alternate 
pathways that are capable of driving the disease phenotype in the absence of RAGE. 
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